

**K. Bibliography** (Peer reviewed articles and book chapters\*)

1. **Press MF**. Lead encephalopathy in neonatal Long-Evans rats: Morphologic studies. *Journal of Neuropathology and Experimental Neurology* 36: 169-193, 1977.
2. **Press MF**. Animal model of human disease: Lead encephalopathy in children. *American Journal of Pathology* 86: 485-488, 1977.
3. **Press MF**. Neuronal development in the cerebellum of lead poisoned neonatal rats. *Acta Neuropathologica* 40: 259-268, 1977.
4. Sundmacher R, **Press M**, Neumann-Haeflin D and Riede U. Keratitis superficialis punctata Thygeson (Thygeson's superficial punctate keratitis). *Klinische Monatsblätter für Augenheilkunde* 170: 908-916, 1977.
5. Warnock M, **Press M**, Churg A. Further observations on pulmonary hyaline. *Human Pathology* 11: 59-65, 1980.
6. **Press MF**, Riddell RH, Ringus J. Cytomegalovirus inclusion disease. Its occurrence in the myenteric plexus of a renal transplant patient. *Archives of Pathology and Laboratory Medicine* 104: 580-583, 1980.
7. Holt JA, Lyttle CR, Lorincz MA, Stern SA, **Press MF**, Herbst AL. Estrogen receptor and peroxidase activity in ovarian adenocarcinomas. *Journal of the National Cancer Institute* 67: 307-318, 1981.
8. Naunheim KS, Kaplan EL, Straus FS II, Sutton HG Jr, **Press MF**, Sugimoto J, Perkins M, Kinsey J. High-dose external radiation to the neck and subsequent thyroid carcinoma. (Chapter 4) in: volume 6, *Clinical Surgery International: Surgery of the Thyroid and Parathyroid Glands*; E. L. Kaplan (ed.), Churchill-Livingston, London, New York, pp. 51-62, 1983.\*
9. **Press MF**, DeSombre ER, Talerma A. Epithelial peroxidase and endometrial granulocytes in the normal cyclic human endometrium. *Journal of Clinical Endocrinology and Metabolism* 57: 254-261, 1983.
10. **Press MF**, Greene GL. An immunocytochemical method for demonstrating estrogen receptor in human uterus using monoclonal antibodies to human estrophilin. *Laboratory Investigation* 50: 480-486, 1984.
11. **Press MF**, Nousek-Goebel NA, King WJ, Herbst AL, Greene GL. Immunohistochemical assessment of estrogen receptor distribution in the human endometrium throughout the menstrual cycle. *Laboratory Investigation* 51: 495-504, 1984.

12. Greene GL, King WJ, **Press MF**. Monoclonal antibodies as probes for estrogen receptor. in: *Endocrinology* edited by Labrie F, Proulx L, Elsevier Publishing, pp. 541-544, 1984.\*
13. **Press MF**. Lead induced permeability changes in the cerebellar microcirculation of rats. *Acta Neuropathologica (Berlin)* 67: 86-95, 1985.
14. **Press MF**, Scully RE. Endometrial sarcomas complicating ovarian thecoma, polycystic ovarian disease and estrogen therapy. *Gynecologic Oncology* 21: 135-154, 1985.
15. Slamon DJ, **Press MF**, Souza LM, Murdock DC, Cline MJ, Golde DW, Gasson JC, Chen ISY. Studies of the putative transforming protein of the human T-cell leukemia virus, type I. *Science* 228: 1427-1430, 1985.
16. **Press MF**, Nousek-Goebel NA, Greene GL. Immunoelectron microscopic localization of estrogen receptor with monoclonal antibodies. *Journal of Histochemistry and Cytochemistry* 33: 915-924, 1985.
17. **Press MF**, Holt JA, Herbst AL, Greene GL. Immunocytochemical localization of estrogen receptor in ovarian carcinomas: Localization with monoclonal estrophilin antibodies compared with biochemical assays. *Laboratory Investigation* 53: 349-361, 1985.
18. Greene GL, King WJ, **Press MF**, Miller LS, Nolan C. Immunochemical studies of estrogen receptor in normal and neoplastic tissues. in: *Monoclonal Antibodies '84: Biological and Clinical Applications*. edited by Pinchera A, Doria G, Dammacco F, Bargellesi A, Kurtis Publishing, Milano, pp. 239-257, 1985.\*
19. Greene GL, King WJ, **Press MF**. Immunocytochemical localization of estrogen receptors with monoclonal antibodies, in: *Immunocytochemistry in Tumor Diagnosis*, edited by Nijhoff M, Russo J, 1985.\*
20. Greene GL, **Press MF**. Structure and dynamics of the estrogen receptor. *Journal of Steroid Biochemistry* 24: 1-7, 1986.
21. **Press MF**, King WJ. Distribution of peroxidase and granulocytes in the human uterus. *Laboratory Investigation* 54: 188-203, 1986.
22. **Press MF**, Nousek-Goebel NA, Bur M, Greene GL. Estrogen receptor localization in the female genital tract. *American Journal of Pathology* 123: 280-292, 1986.
23. Nousek-Goebel NA, **Press MF**. Golgi-Electron microscopic study of endothelial sprouts in the neonatal rat cerebellar cortex. *Developmental Brain Research* 30: 67-73, 1986.
24. Slamon DJ, Boon T, Murdock DC, Keith D, **Press MF**, Larson RA, Souza LM. Studies of human *c-myb* gene and its product in human acute leukemias. *Science* 233: 347-351, 1986.
25. Greene GL, King WJ, **Press MF**, Jensen EV. Antibodies to estrogen receptor: New probes for the analysis of receptor structure and function. in: *Estrogen and Antiestrogen Action*, edited by VC Jordan, University of Wisconsin Press, Madison, 1986.\*

26. Bur ME, Greene GL, **Press MF**. Estrogen receptor localization in paraffin embedded endometrium and endometriotic tissue. *International Journal of Gynecological Pathology* 6: 140-151, 1987.
27. **Press MF**, Greene GL. Recent Developments in the use of anti-receptor antibodies to study hormone receptors. in: *Steroid Hormone Receptors: Their intracellular localization*, edited by Clark CR, Ellis Horwood Ltd Publishing (UK), pp. 251-275, 1987.\*
28. Greene GL, **Press MF**. Immunochemical evaluation of estrogen receptor and progesterone receptor in breast cancer. in: *Immunological Approaches to the Diagnosis and Therapy of Breast Cancer*, edited by Roberto L. Ceriani, Plenum Publishing Corp., pp. 119-135, 1987\*.
29. Jones LA, **Press MF**, Holt JA, Gallagher HS, Freedman RS, Edwards CL. Comparison of immunologic and steroid-binding assays for estrogen receptors in ovarian carcinoma. 29th Annual Clinical Conference on Cancer: Diagnosis of Treatment Strategies for Gynecologic Cancer. U.T. M.D. Anderson 1985 *Clinical Conference on Gynecologic Oncology* 29: 111-121, 1987. \*
30. Yamada T, **Press M**, Vesselinovitch D, Wissler RW. Quantitative ultrastructural analysis of coronary atherosclerotic involvement in two Macaque species. *Experimental Molecular Pathology* 48: 1-23, 1988.
31. **Press MF**, Greene GL. Localization of progesterone receptor with monoclonal antibodies to the human progesterin receptor. *Endocrinology* 122: 1165-1175, 1988.
32. Slamon DJ, Boyle WJ, **Press MF**, Golde DW, Souza L. Subnuclear localization of the trans-activating protein of the human T-cell leukemia virus, type I. *Journal of Virology* 62: 680-686, 1988.
33. **Press MF**, Udove JA, Greene GL. Progesterone receptor distribution in the human endometrium: Analysis using monoclonal antibodies to human progesterin receptor. *American Journal of Pathology* 131: 112-124, 1988.
34. **Press MF**, Greene, GL. Immunocytochemical localization of estrogen receptor and progesterone receptor. in: *Advances in Immunohistochemistry*, edited by DeLellis RA, Raven Press Medical and Scientific Publishers, New York, pp. 341-362, 1988. \*
35. Bacus S, Flowers J, **Press M**, Bacus J, McCarty K, Jr. The evaluation of estrogen receptor in primary breast carcinoma by computerized image analysis. *American Journal of Clinical Pathology* 90: 233-239, 1988.
36. Rotmensch J, Hines J, Grdina D, **Press MF**, Beckett M, Schwartz J, Herbst AL, Weichselbaum RR. The potential use of alpha-emitting isotopes in the treatment of experimental human ovarian carcinoma. *Gynecologic Oncology* 32: 236-239, 1989.

37. Senekjian EK, **Press MF**, Blough RR, Herbst AL, DeSombre ER. Comparison of the quantity of estrogen receptors in human endometrium and myometrium by steroid binding assay and enzyme immunoassay based on monoclonal antibodies to human estrophilin. *American Journal of Obstetrics and Gynecology* 160: 592-597, 1989.
38. Slamon DJ, Godolphin W, Jones LA, Holt JA, Wong SG, Keith DE, Levin WJ, Stuart SG, Udove J, Ullrich A, **Press MF**. Studies of the HER-2/*neu* proto-oncogene in human breast and ovarian cancer. *Science* 244: 707-712, 1989 (cover illustration taken from our report)
39. Halper J, Colvard DS, Scheithauer BW, Jiang N-S, **Press MF**, Graham ML II, Riehl E, Laws ER Jr, Spelsberg TC. Estrogen and progesterone receptor in meningiomas: Comparison of nuclear binding, dextran-coated charcoal and immunoperoxidase staining assays. *Neurosurgery*. 25: 546-553, 1989.
40. **Press MF**, Xu S-H, Wang J-D, Greene GL. Subcellular distribution of estrogen receptor and progesterone receptor with and without specific ligand. *American Journal of Pathology* 135: 857-864, 1989.
41. Slamon DJ, **Press MF**, Godolphin W, Ramos L, Haran P, Shek L, Stuart SG, Ullrich A. Studies of the HER-2/*neu* proto-oncogene in human breast cancer. *Cancer Cells* 7: 371-380, 1989.
42. Bacus S, Bacus J, Slamon DJ, **Press MF**. HER-2/*neu* oncogene expression and DNA ploidy analysis in breast cancer. *Archives of Pathology and Laboratory Medicine* 114: 164-169, 1990.
43. **Press MF**, Jones LA, Godolphin W, Edwards CL, Slamon DJ. HER-2/*neu* oncogene amplification and expression in breast and ovarian cancers. *Progress in Clinical & Biological Research*. 354A: 209-21, 1990\*
44. **Press MF**, Cordon-Cardo C, Slamon DJ. Expression of the HER-2/*neu* Proto-oncogene in Normal Adult and Fetal Tissues. *Oncogene* 5: 953-962, 1990. PMID:1973830
45. **Press MF**. Oncogene amplification and expression. Importance of methodologic considerations. *American Journal of Clinical Pathology* 94: 240-241, 1990.
46. **Press MF**, Pike MC, Chazin VR, Hung G, Udove JA, Markowicz M, Danyluk J, Godolphin W, Sliwkowski M, Akita R, Brandeis J, Paterson MC, Slamon DJ. HER-2/*neu* expression in node-negative breast cancers: Direct tissue quantitation by computerized image analysis and association of overexpression with increased risk of recurrent disease. *Cancer Research* 53: 4960-4970, 1993.
47. Sauer MV, Miles RA, Dahmouh L, Paulson RJ, **Press MF**, Moyer DL. Evaluating the effect of age on endometrial responsiveness to hormone replacement therapy: A histologic, ultrasonographic and tissue receptor analysis. *J. Assist. Reprod. Genetics*. 10: 47-52, 1993.
48. Kieback DG, McCamant SK, **Press MF**, Atkinson EN, Gallagher HS, Edwards CL, Jones LA. Improved prediction of survival in advanced adenocarcinoma of the ovary by

- immunocytochemical analysis and the composition adjusted receptor level of the estrogen receptor. *Cancer Research* 53: 5188-5192, 1993.
49. **Press MF**. Estrogen and progesterone receptors in breast cancer. *Advances in Pathology and Laboratory Medicine* 6: 117-148, 1993.
  50. Dahmouh L, Pike MC, **Press MF**. Hormones and breast cell proliferation. in Treatment of the Postmenopausal Woman: Basic and Clinical Aspects. ed. by R. A. Lobo, Raven Press, New York, pp. 325-337, 1993.\*
  51. Pike MC, Spicer D, Dahmouh L, **Press MF**. Estrogens, progestogens, normal breast cell proliferation and breast cancer risk. *Epidemiologic Review* 15: 17-35, 1993.
  52. Kieback DG, **Press MF**, Atkinson EN, Mobus VJ, Runnebaum IB, Kreienberg R, Jones LA. Prognostic significance of estrogen receptor expression in ovarian cancer. Immunoreactive score (IRS) vs. composition adjusted receptor level (CARL). *Anticancer Research* 13: 2489-2496, 1993.
  53. Miles RA, Palson RJ, Lobo RA, **Press MF**, Dahmouh L, Sauer MV. Pharmacokinetics and endometrial tissue levels of progesterone after administration by intramuscular and vaginal routes: A comparative study. *Journal of Fertility and Sterility*. 62: 485-490, 1994.
  54. **Press MF**, Hung G, Godolphin W, Slamon DJ. Sensitivity of HER-2/*neu* antibodies in archival tissue samples: Potential source of error in immunohistochemical studies of expression. *Cancer Research* 54: 2771-2777, 1994.
  55. **Press MF**, Pike MC, Hung G, Zhou J-Y, George J, Dietz-Band J, James W, Slamon DJ, Batsakis JG, El-Naggar AK. Amplification and overexpression of HER-2/*neu* in carcinomas of the salivary gland: Correlation with poor prognosis. *Cancer Research* 54: 5675-5682, 1994.
  56. Strohmeyer T, Reese D, **Press M**, Ackermann R, Hartmann M, Slamon D. Expression of the *c-kit* proto-oncogene and its ligand 'stem cell factor (SCF)' in normal and malignant human testicular tissue. *Journal of Urology* 153: 511-515, 1995.
  57. Levin WJ, **Press MF**, Gaynor RB, Sukhatme VP, Boone TC, Reissmann PT, Gifflin RA, Holmes EC, Souza LM, Slamon DJ. Expression patterns of immediate early transcription factors in non-small cell lung cancer. *Oncogene* 11: 1261-1269, 1995.
  58. Kieback DG, **Press MF**, McCamant SK, Atkinson EN, Mobus VJ, Runnebaum IB, Kreienberg R, Jones LA. Die prognostische differenzierung von ovarialkarzinomen durch immunhistochemische analyse der ostrogenrezeptorexpression. *Geburtshilfe und Frauenheilkunde* 55: 189-194, 1995.
  59. Saffari B, Jones LA, El-Naggar A, Felix JC, George J, **Press MF**. Amplification and overexpression of HER-2/*neu* (*c-erb B-2*) in endometrial cancers: Correlation with overall survival. *Cancer Research* 55: 5693-5698, 1995.

60. Reles A, **Press MF**, Schonborn I, Friedmann W, Minguillon C, Lichtenegger W, Strohmeyer T. Immunohistochemical detection of p53 protein in ovarian carcinoma: Correlation with histopathological data and clinical follow up. *Gynakologisch Geburtshilfliche Rundschau* 35: 93-97, 1995.
61. Felix A, El-Naggar A, **Press MF**, Ordonez N, Fonseca I, Tucker S, Luna M and Batsakis J. Prognostic significance of biomarkers (c-erb B-2, p53, proliferating cell nuclear antigen, and DNA content) in salivary duct carcinoma. *Human Pathology* 27(6): 561-6, 1996.
62. Shibata A, Tsai YC, **Press MF**, Henderson BE, Jones PA, Ross RK. Clonal analysis of bilateral breast cancer. *Clinical Cancer Research* 2: 743-748, 1996.
63. Pauletti G, Godolphin W, **Press MF**, Slamon DJ. Detection and quantitation of HER-2/*neu* gene amplification in human breast cancer archival material using fluorescence *in situ* hybridization. *Oncogene* 13: 63-72, 1996.
64. Hsu Y-H, Zhou J-Y, **Press MF**. Amplification and overexpression of HER-2/*neu* in breast carcinomas from eastern Taiwan-Hualien. *Tzu Chi Med J.* 8: 183-189, 1996.
65. Kieback DG, Levy T, Kohlberger P, Fiedrich U, **Press MF**, Rosenthal HE, Mobus VJ, Runnebaum IB, Tong W-W, Gause HM, Tsai M-J. Chicken ovalbumin upstream promoter - transcription factor (COUP-TF) expression in human endometrial cancer cell lines. *Anticancer Research* 16: 3371-3376, 1996.
66. Reles A, Schmider A, **Press M**, Schonborn I, Friedmann W, Huber-Schumacher S, Strohmeyer T, Lichtenegger W. Immunohistochemical detection of p53 protein in ovarian carcinoma: Correlation with histopathological data and clinical follow up. *Journal of Cancer Research and Clinical Oncology* 122: 489-494, 1996.
67. Lukas J, Groshen S, Saffari B, Niu N, Reles A, Wen W-H, Felix J, Jones LA, Hall FL, **Press MF**. WAF1/Cip gene polymorphism and expression in carcinomas of the breast, ovary and endometrium. *American Journal of Pathology* 150: 167-175, 1997.
68. Tsao J-I, Zhao Y, Lukas J, Yang X, Shah A, **Press MF**, Shibata D. Telomerase activity in normal and neoplastic breast. *Clinical Cancer Research* 3: 627-631, 1997.
69. **Press MF**, Bernstein L, Thomas PA, Meisner LF, Zhou J-Y, Ma Y, Hung G, Robinson RA, Harris C, El-Naggar A, Slamon DJ, Peyrot M, Ross J, Phillips R, Wolman SR, Flom KJ. HER-2/*neu* gene amplification by fluorescence *in situ* hybridization: Poor prognosis in node-negative breast carcinomas. *Journal of Clinical Oncology* 15: 2894-2904, 1997.
70. Petrosyan K, **Press MF**. Multispecimen tissue blocks in pathology: An improved technique of preparation. *Laboratory Investigation* 77: 541-542, 1997.
71. Formenti SC, Dunnington G, Lenz H-J, Uzieli B, Keren-Rosenberg S, Silberman H, Spicer D, Denk M, Leichman G, Groshen S, Watkins K, Muggia F, Florentine B, **Press M**, Danenberg K, Danenberg P. Original p53 status predicts for pathological response in locally advanced breast cancer patients treated pre-operatively with continuous infusion (C.I.) 5-

- fluorouracil (5-FU) and radiation therapy. *International Journal of Radiation Oncology, Biology, and Physics* 39: 1059 - 1068, 1997.
72. **Press MF.** Are Synchronous Uterine and Ovarian Carcinomas Independent Primary Tumors? *Advances in Anatomic Pathology* 4: 370-372, 1997.
  73. **Press MF.** Sixth biennial symposium on minorities, the medically underserved and cancer: Gynecological cancers. *Cancer (Supplement)* 83: 1751-1756, 1998.
  74. Bernstein L, **Press M.** Does estrogen receptor expression in normal breast tissue predict breast cancer risk? *Journal of the National Cancer Institute* 90: 5-7, 1998.
  75. Wang-Gohrke S, Hees S, Pochon A, Wen W-H, Reles A, **Press MF**, Kreienberg R, Runnebaum IB. Genomic semiautomated cycle sequencing as a sensitive screening technique for p53 mutations in frozen tumor samples. *Oncology Reports* 5: 65-68, 1998.
  76. Reles A, Gee C, Schellschmidt I, Schmider A, Unger M, Friedmann W, Lichtenegger W, **Press M.** Prognostic significance of DNA content and S-phase fraction in epithelial ovarian carcinomas analyzed by image cytometry. *Gynecologic Oncology* 71: 3-13, 1998.
  77. Wen W-H, Reles A, Runnebaum I, Sullivan-Halley J, Bernstein L, Jones LA, Felix JC, Kreienberg R, El-Naggar A, **Press MF.** p53 mutations and expression in ovarian cancers: Correlation with overall survival. *International Journal of Gynecological Pathology* 18: 29-41, 1999.
  78. Yang X, Uziely B, Groshen S, Lukas J, Israel V, Russell C, Dunnington G, Formenti S, Muggia F, **Press M.** MDR1 gene expression in primary and advanced breast cancer. *Laboratory Investigation* 79: 271-280, 1999.
  79. Park J, Pike MC, Park J, **Press MF.** Hormones and breast cell proliferation. in Treatment of the Postmenopausal Woman: Basic and Clinical Aspects. ed. by R. A. Lobo, Raven Press, New York, pp. 473-486, 1999.\*
  80. Mitchell M, **Press MF.** The role of immunohistochemistry and fluorescence *in situ* hybridization for HER-2/*neu* in assessing the prognosis for breast cancer. *Seminars in Oncology (Suppl.)* 26: 108-116, 1999.
  81. Cozen W, Bernstein L, Wang F, **Press MF**, Mack TM. The risk of angiosarcoma following primary breast cancer. *British Journal of Cancer* 81: 532-536, 1999.
  82. Wilson CA, Ramos L, Villasenor MR, Anders KH, **Press MF**, Clarke K, Karlan B, Chen J-J, Scully R, Livingston D, Zuch RH, Kanter MH, Cohen S, Calzone FJ, Slamon DJ. Localization of human BRCA1 and its loss in high-grade, non-inherited breast carcinomas. *Nature Genetics* 21: 236-240, 1999.
  83. Park JM, Yang X, Park J, Press O, **Press M.** Assessment of novel anti-p185<sup>HER-2</sup> monoclonal antibodies for internalization-dependent therapies. *Hybridoma* 18: 487-495, 1999.

84. Wen W-H, Bernstein L, Lescallett J, Barclay Y, Sullivan-Halley J, White M, **Press MF**. Comparison of *TP53* mutations identified by oligonucleotide microarray and conventional DNA sequence analysis. *Cancer Research* 60: 2716-2722, 2000.
85. Lukas J, Niu N, **Press MF**. P53 mutations and expression in breast carcinoma *in situ*. *American Journal of Pathology* 156: 183-191, 2000.
86. Zheng W, Luo F, Baltayan A, Lu J, Brader K, **Press M**, Zhang ZF, Pike MC. Reduction of BRCA1 expression in sporadic ovarian cancer. *Gynecologic Oncology* 76(3): 294-300, 2000.
87. Schmider A, Gee C, Friedmann W, Lukas JJ, **Press MF**, Lichtenegger W, Reles A. p21 (WAF1/Cip1) protein expression is associated with prolonged survival but not with p53 expression in epithelial ovarian carcinomas. *Gynecologic Oncology* 77: 237-242, 2000.
88. Park JJ, Irvine RA, Buchanan G, Koh SS, Park JM, Tilley WD, Stallcup MR, **Press MF**, Coetzee GA. BRCA1 is a coactivator of the androgen receptor. *Cancer Research* 60: 5946-5949, 2000.
89. Lukas J, Gao D-Q, Keshmeshian M, Wen W-H, Wei D, Rosenberg S, **Press MF**. Alternative and aberrant messenger RNA splicing of the *mdm2* oncogene in invasive breast cancer. *Cancer Research* 61: 3212-3219, 2001.
90. Reles A, Wen WH, Gee C, Runnebaum IB, Schmider A, Jones LA, El-Naggar A, Minguillon C, Reich O, Kreienberg R, Lichtenegger W, **Press MF**. Correlation of p53 mutations with resistance to platinum-based chemotherapy and shortened survival in ovarian cancer. *Clinical Cancer Research* 7: 2984-2997, 2001.
91. McKean-Cowdin R, Kolonel LN, **Press MF**, Pike MC, Henderson BE. Germ-line HER-2 Variant and Breast Cancer Risk by Stage of Disease. *Cancer Research* 61(23):8393-8394, 2001.
92. Marchbanks PA, McDonald JA, Wilson HG, Burnett NM, Daling JR, Bernstein L, Malone KE, Strom BL, Norman SA, Weiss LK, Liff JM, Wingo PA, Burkman RT, Folger SG, Berlin JA, Ursin G, Deapen DM, Coates RJ, Simon MS, **Press MF**, Spirtas R. The NICHD Women's Contraceptive and Reproductive Experiences Study: Methods and Operational Results. *Annals of Epidemiology* 12: 213-221, 2002.
93. Vogel CL, Cobleigh MA, Tripathy D, Gutheil JC, Harris LN, Fehrenbacher L, Slamon DJ, Murphy M, Novotny WF, Burchmore M, Shak S, Stewart SJ, **Press MF**. Efficacy and safety of trastuzumab (Herceptin) as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer. *Journal of Clinical Oncology* 20: 719-726, 2002.
94. **Press MF**, Slamon DJ, Flom KJ, Park J, Zhou J-Y, Bernstein L. Evaluation of HER-2/*neu* Gene Amplification and Overexpression: Comparison of Frequently Used Assay Methods in a Molecularly Characterized Cohort of Breast Cancer Specimens. *Journal of Clinical Oncology* 20: 3095-3105, 2002.

95. **Press MF**, Spaulding B, Groshen S, Kaminsky D, Hagerty M, Sherman L, Christensen K, Edwards DP. Monoclonal antibodies designed for immunohistochemical detection of progesterone receptor in archival breast cancer specimens. *Steroids* 67: 799-813, 2002.
96. Schmitt IA and **Press MF**. HER-2/*neu* Gene Amplification and Overexpression in Ductal Carcinoma *in Situ*. in Ductal Carcinoma In Situ of the Breast, 2<sup>nd</sup> Edition, edited by Melvin Silverstein. Williams and Wilkins, pp. 54-66, 2002.
97. Mack TM, Hamilton AS, **Press MF**, Diep A, Rappaport EB. Understanding heritable breast cancer from the pattern in twins. *British Journal of Cancer* 87: 294-300, 2002.
98. Formenti SC, Spicer D, Skinner K, Cohen D, Groshen S, Bettini A, Naritoku W, **Press M**, Salonga D, Tsao-Wei D, Danenberg K, Danenberg P. Low HER2/*neu* gene expression is associated with pathological response to concurrent paclitaxel and radiation therapy in locally advanced breast cancer. *International Journal of Radiation Oncology, Biology, and Physics*. 52: 397-405, 2002.
99. **Press MF**, Bernstein L, Flom K, Slamon DJ. In Reply: FDA-approved HercepTest is far less sensitive for detection of breast cancer. *Journal Clinical Oncology* 20 (23): 4607-4609, 2002.
100. Schmitt IA, Dolezal M, **Press MF**. Progression from Hormone-Dependent to Hormone-Independent Breast Cancer in Hormones, Genes and Cancer edited by Brian Henderson, Bruce Ponder and Ronald Ross. Oxford University Press, Inc., pp. 255-272, 2003.
101. Yang X, Groshen S, Formenti S, Davidson NE, **Press MF**. P7 antigen expression in human breast cancer. *Clinical Cancer Research* 9(1): 201-206, 2003.
102. Tai C-K, Logg CR, Park JM, Anderson WF, **Press MF**, Kasahara N. Antibody-mediated targeting of replication-competent retroviral vectors. *Human Gene Therapy* 14: 789-802, 2003.
103. Formenti SC, Volm M, Skinner KA, Spicer D, Cohen D, Perez E, Bettini AC, Groshen S, Gee C, Florentine B, **Press M**, Danenberg P, Muggia F. Preoperative twice-weekly paclitaxel with concurrent radiation therapy followed by surgery and postoperative doxorubicin-based chemotherapy in locally advanced breast cancer: a phase I/II trial. *Journal of Clinical Oncology* 21: 864-870, 2003.
104. Patel AV, **Press MF**, Meeske K, Calle EE, Bernstein L. Lifetime recreational exercise activity and risk of breast carcinoma *in situ*. *Cancer*. 98(10): 2161-9, 2003.
105. Olafsen T, Tan GJ, Park JM, Crow D, Shively JE, Williams LE, Raubitschek AA, **Press MF**, Wu AM. Construction and characterization of novel minibodies (SCVF-C<sub>H3</sub>) against HER2/*neu*. *Protein Engineering, Design and Selection* 17: 315-323, 2004.
106. Meeske K, **Press M**, Patel A, Bernstein L. Impact of reproductive factors and lactation on breast carcinoma *in situ* risk. *International Journal of Cancer* 110: 102-109, 2004.

107. Wen W-H, **Press MF**. Identification of *TP53* mutations in human cancers using oligonucleotide microarrays. *Methods in Molecular Medicine* 97: 323-335, 2004.
108. Pegram MD, Pienkowski T, Northfelt D, Eiermann W, Patel R, Fumoleau P, Quan E, Crown J, Toppmeyer D, Smylie M, Riva A, Blitz S, **Press M**, Reese D, Lindsay M-A, Slamon DJ. Results of Two Open Label Multicenter Phase II Studies of the Synergistic, Non-anthracycline Based Combination of Docetaxel, Platinum Salt, and Trastuzumab in HER2-Positive Advanced Breast Cancer. *Journal of the National Cancer Institute* 96(10): 759-769, 2004.
109. Enger SM, Greif JM, Polikoff J, **Press MF**. Body weight correlates with mortality in early stage breast cancer. *Archives of Surgery* 139: 954-960, 2004.
110. Simon MS, Korczak JF, Yee CL, Daling JR, Malone KE, Bernstein L, Marchbanks PA, Folger SG, McDonald JA, Norman SA, Strom BL, Deapen D, Ursin G, Burkman RT, **Press MF**, Schwartz AG, Spirtas R. Racial differences in the familial aggregation of breast cancer and other female cancers in the Women's Contraceptive and Reproductive Experiences (CARE) study. *Breast Cancer Research and Treatment* 89: 227-235, 2005.
111. Lippman ME, Benz C, Chinnaiyan A, Flockhart D, Harris A, Hudis C, Osborne CK, **Press MF**, Rae J, Sledge GW, Van't Veer L, Wicha M. Consensus statement: Expedition Inspiration 2004 Breast Cancer Symposium 'Breast Cancer--The Development and Validation of New Therapeutics. *Breast Cancer Research and Treatment*. 90(1): 1-3, 2005.
112. Agus DB, Gordon MS, Taylor C, Natale RB, Karlan B, Mendelson DS, **Press MF**, Allison DE, Sliwkowski MX, Lieberman G, Kelsey SM, Fyfe G. Phase I clinical study of pertuzumab, a novel HER dimerization inhibitor, in patients with advanced cancer. *Journal of Clinical Oncology* 23(11): 2534-2543, 2005.
113. Saffari B, Bernstein L, Runnebaum IB, Hong DC, Grill H-J, Jones LA, El-Naggar A, **Press MF**. *P53* mutations and codon 72 Arg/Pro allelotype are associated with a lower overall survival rate and may serve as a marker of responsiveness to adjuvant radiotherapy in endometrioid endometrial carcinoma. *International Journal of Gynecologic Cancer* 15: 952-963, 2005.
114. Dybdal N, Lieberman G, Anderson S, Bajamonde A, Cohen RL, Mass RD, Sanders C, **Press MF**. Determination of HER2 gene amplification by fluorescence *in situ* hybridization and concordance with the clinical trials immunohistochemical assay in women with metastatic breast cancer evaluated for treatment with trastuzumab. *Breast Cancer Research and Treatment* 93: 3-11, 2005.
115. Mass RD, **Press MF**, Anderson S, Cobleigh MA, Vogel CL, Dybdal N, Lieberman G, Slamon DJ. Evaluation of clinical outcomes according to HER2 detection by fluorescence *in situ* hybridization in women with metastatic breast cancer treated with trastuzumab. *Clinical Breast Cancer* 6: 240-246, 2005.

116. Ursin G, Bernstein L, Lord SJ, Karim R, Deapen D, **Press MF**, Daling JR, Norman SA, Liff JM, Marchbanks PA, Folger SG, Simon MS, Strom BL, Burkman RT, Weiss LK, Spirtas R. Reproductive factors and subtypes of breast cancer defined by hormone receptor and histology. *British Journal of Cancer* 939(3): 364-371, 2005.
117. Bernstein L, Patel AV, Ursin G, Sullivan-Halley J, **Press MF**, Deapen D, Berlin JA, Daling JR, MacDonald JA, Norman SA, Malone KE, Strom B, Liff J, Folger SG, Simon MS, Burkman RT, Marchbanks PA, Weiss LK, Spirtas R. Lifetime recreational exercise activity and breast cancer risk among black and white women. *Journal of the National Cancer Institute* 97: 1671 – 1679, 2005.
118. Olafsen T, Kenanova V, Sundaresan G, Anderson A-L, Crow D, Li L, **Press MF**, Gambhir SS, Williams LE, Wong JYC, Raubitschek AA, Shively JE, Wu AM. Optimizing radiolabeled engineered anti-p185<sup>HER2</sup> antibody fragments for in vivo imaging. *Cancer Research* 65: 5907-5916, 2005.
119. **Press MF**, Sauter G, Bernstein L, Villalobos I, Mirlacher M, Zhou J-Y, Wardeh R, Li B, Guzman R, Santiago A, Ma Y, Sullivan-Halley J, Park JM, Riva A, Slamon DJ. Diagnostic Evaluation of HER-2 as a Molecular Target: An Assessment of Accuracy and Reproducibility of Laboratory Testing in Large, Prospective, Randomized Clinical Trials. *Clinical Cancer Research* 11: 6598-6607, 2005.
120. Li CI, Daling JR, Malone KE, Bernstein L, Marchbanks PA, Liff JM, Strom BL, Simon MS, **Press MF**, McDonald JA, Ursin G, Burkman RT, Deapen D, Spirtas R. Relationship between established breast cancer risk factors and risk of seven different histologic types of invasive breast cancer. *Cancer Epidemiology Biomarkers & Prevention*. 15(5): 946-954, 2006.
121. Simon MS, Korczak JF, Yee CL, Malone KE, Ursin G, Bernstein L, McDonald JA, Deapen D, Strom BL, **Press MF**, Marchbanks PA, Burkman RT, Weiss LK, Schwartz AG. Breast cancer risk estimates for relatives of white and African American women with breast cancer in the Women's Contraceptive and Reproductive Experiences Study. *Journal of Clinical Oncology* 24(16): 2498-504, 2006.
122. Gill J, **Press M**, Patel AV, Bernstein L. Oral contraceptive use and risk of breast carcinoma *in-situ*. *Cancer Causes and Control* 17: 1155–1162, 2006.
123. Epstein M, Ma Y, **Press MF**. Herceptin (Trastuzumab) in the Adjuvant Setting: The Need for Accurate HER-2 Testing in Breast Cancer. *Advances in Anatomic Pathology* 13(4): 200-201, 2006.
124. Kumar SR, Singh J, Xia G, Krasnoperov V, Hassanieh L, Ley EJ, Schemet J, Kumar NG, Hawes D, **Press MF**, Weaver FA, Gill PS. Receptor Tyrosine Kinase EphB4 Is a Survival Factor in Breast Cancer. *American Journal of Pathology* 169 (1): 279-293, 2006.
125. Carlson RW, Moench SJ, Hammond ME, Perez EA, Burstein HJ, Allred DC, Vogel CL, Goldstein LJ, Somlo G, Gradishar WJ, Hudis CA, Jahanzeb M, Stark A, Wolff AC, **Press MF**, Winer EP, Paik S, Ljung BM. HER2 Testing in Breast Cancer: NCCN Task Force

Report and Recommendations. *Journal of the National Comprehensive Cancer Network* Jul; 4 Suppl 3:S1-S22, 2006.

126. **Press MF**, How Is HER2 Status established when HER2 and chromosome 17 centromere are both amplified? *American Journal of Clinical Pathology* 126(5): 673-674, 2006.
127. Gatto NM, Longnecker MP, **Press MF**, Sullivan-Halley J, McKean Cowdin R, Bernstein L. Serum organochlorines and breast cancer: a case-control study among African-American women. *Cancer Causes Control*. 18(1): 29-39, 2007.
128. Christensen DL, Liff JM, Coates RJ, Flagg EW, Daling JR, Malone KE, MacDonald JA, Folger SG, Marchbanks PA, Strom B, **Press MF**, Simon M, Burkman R, Bernstein L, Norman S, Spiritas R. Birth Weight and Breast Cancer Risk in the Women's Contraceptive and Reproductive Experiences Study. *American Journal of Epidemiology*. (in review), 2008.
129. **Press MF**, Lenz HJ. EGFR, HER2 and VEGF Pathways: Validated targets for treatment. *Drugs* 67(14): 2045-2075, 2007.
130. Wolff AC, Hammond ME, Schwartz JN, Hagerty KL, Allred DC, Cote RJ, Dowsett M, Fitzgibbons PL, Hanna WM, Langer A, McShane LM, Paik S, Pegram MD, Perez EA, **Press MF**, Rhodes A, Sturgeon C, Taube SE, Tubbs R, Vance GH, van de Vijver M, Wheeler TM, Hayes DF. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. *Journal of Clinical Oncology*. 25(1): 118-145, 2007.
131. Haiman CA, Setiawan VW, Xia LY, Marchand LL, Ingles SA, Ursin G, **Press MF**, Bernstein L, John EM, Henderson BE. A Variant in the Cytochrome P450 Oxidoreductase Gene is Associated with Breast Cancer Risk in African Americans. *Cancer Research* 67(8): 3565-3568, 2007.
132. Wolff AC, Hammond MEH, Schwartz JN, Hagerty KL, Allred DC, Cote RJ, Dowsett M, Fitzgibbons PL, Hanna WM, Langer A, McShane LM, Paik S, Pegram MD, Perez EA, **Press MF**, Rhodes A, Sturgeon C, Taube SE, Tubbs R, Vance GH, van de Vijver M, Wheeler TM, Hayes DF. American Society of Clinical Oncology/College of American Pathologists Guideline Recommendations for Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer. *Archives of Pathology and Laboratory Medicine* 131: 18-43, 2007.
133. Li CI, Malone KE, Daling JR, Potter JD, Bernstein L, Marchbanks PA, Strom BL, Simon MS, **Press MF**, Ursin G, Burkman RT, Fogler SG, Norman S, MacDonald JA, Spiritas R. Timing of menarche and first full-term birth in relation to breast cancer risk. *American Journal of Epidemiology* 167: 230-239, 2008.
134. Setiawan VW, Chu LH, John EM, Ding YC, Ingles SA, Bernstein L, **Press MF**, Ursin G, Haiman CA, Neuhausen SL. Mitochondrial DNA G10398A variant is not associated with

- breast cancer in African-American women. *Cancer Genetics and Cytogenetics* 181: 16-19, 2008.
135. Lord SJ, Bernstein L, Johnson KA, Malone KE, McDonald JA, Marchbanks PA, Simon MS, Strom BL, **Press MF**, Folger SG, Burkman RT, Deapan D, Spirtas Robert, Ursin G. Breast cancer risk and hormone receptor status in older women by parity, age of first birth, and breastfeeding - a case-control study. *Cancer Epidemiology, Biomarkers and Prevention* 7: 1723-1730, 2008.
  136. Cameron D, Casey M, **Press M**, Lindquist D, Pienkowski T, Romieu CG, Chan S, Jagiello-Gruszfeld A, Kaufman B, Crown J, Chan A, Campone M, Viens P, Davidson N, Gorbounova V, Raats JI, Skarlos D, Newstat B, Roychowdhury D, Paoletti P, Oliva C, Rubin S, Stein S, Geyer CE. A Randomized Comparison of Lapatinib Plus Capecitabine Versus Capecitabine Alone in Women with Advanced Breast Cancer that has Progressed on Trastuzumab: Updated Efficacy and Biomarker Analyses. *Breast Cancer Research and Treatment* 112(3): 533-543, 2008.
  137. Di Leo A, Gomez HL, Aziz Z, Zvirbule Z, Bines J, Arbushites MC, Guerrero SF, Koehler M, Oliva C, Stein SH, Williams LS, Dering J, Finn RS, **Press MF**. Lapatinib plus paclitaxel versus placebo plus paclitaxel as first-line treatment for patients with metastatic breast cancer: A phase III, double-blind, randomized study in 580 Patients. *Journal of Clinical Oncology* 26(34): 5544-5552, 2008.
  138. **Press MF**, Finn RS, Cameron D, Di Leo A, Geyer CE, Villalobos IE, Santiago A, Guzman R, Gasparyan A, Ma Y, Danenberg K, Martin AM, Williams L, Oliva C, Stein S, Gagnon R, Arbushites M, Koehler MT. HER2 Gene Amplification, HER2 and EGFR Messenger RNA and Protein Expression and Lapatinib Efficacy in Women with Metastatic Breast Cancer. *Clinical Cancer Research* 14: 7861-7870, 2008.
  139. Bektas N, Noetzel E, Veeck J, **Press MF**, Kristiansen G, Naami A, Hartmann A, Dimmler A, Beckmann MW, Knuechel R, Fasching PA, Dahl E. The ubiquitin-like molecule interferon-stimulated gene 15 (ISG15) is a potential prognostic marker in human breast cancer. *Breast Cancer Res* 4: R58, 2008.
  140. Konecny GE, Santos L, Hatmal M, Winterhoff B, Keeney GL, Mariani A, Jones M, Neuper C, Muderspach L, Riehle D, Wang H-J, Dowdy S, Podratz KC, **Press MF**. HER2 gene amplification and EGFR expression in a large cohort of surgically staged patients with nonendometrioid (type II) endometrial cancer. *British Journal of Cancer* 100(1): 89-95, 2009.
  141. Sauter G, Lee J, Bartlett JMS, Slamon DJ, **Press MF**. Guidelines for human epidermal growth factor receptor 2 testing: biologic and methodologic considerations. *Journal of Clinical Oncology* 27: 1323-1333, 2009.
  142. Epstein M, Ma Y, **Press MF**. "HER-2/*neu* Testing: Assessment of Status for Targeted Therapies", in *Diseases of the Breast* edited by Harris JR, Lippman ME, Morrow M, and Osborne CK, pp. 431-422, 2009\*.

143. Ioan A, Klobocista M, Shirazi S, **Press MF**. “Molecular oncology of breast cancer”, in 4th edition of The Breast: Comprehensive Management of Benign and Malignant Diseases by Bland KI & Copeland EM (editors) Saunders Elsevier, pp. 501-532, 2009.
144. Ma H, Luo J, **Press MF**, Bernstein L, Ursin G. Is there a difference in the association between mammographic density and subtypes of breast cancer? - Luminal A and basal-like breast cancer. *Cancer Epidemiology, Biomarkers and Prevention* 18 (2): 479-485, 2009.
145. Finn RS, Gagnon R, Di Leo A, **Press MF**, Arbushites M, Koehler M. Prognostic and predictive value of HER2 extracellular domain in metastatic breast cancer (MBC) treated with lapatinib and paclitaxel in a randomized Phase III study. *Journal of Clinical Oncology* 27(33): 5552-5558, 2009.
146. Udler MS, Meyer KB, Pooley KA, Karlins E, Struewing JP, Zhang J, Doody DR, MacArthur S, Tyrer J, Pharoah PD, Luben R, SEARCH Collaborators, Bernstein L, Kolonel LN, Henderson BE, Le Marchand L, Ursin G, **Press MF**, Brennan P, Sangrajrang S, Gaborieau V, Odefrey F, Shen C-Y, Wu P-E, Wang H-C, Kang D, Yoo K-Y, Noh D-Y, Ahn S-H, Ponder BAJ, Haiman CA, Malone KE, Dunning AM, Ostrander EA, Easton DF. FGFR2 variants and breast cancer risk: fine-scale mapping using African American studies and analysis of chromatin conformation. *Human Molecular Genetics* 9: 1692-1703, 2009.
147. Fejerman L, Haiman CA, Reich D, Tandon A, Deo RC, John EM, Ambrosone C, Whittemore A, Bernstein L, Henderson BE, John EM, **Press MF**, Ursin G, Huntsman S, Ziv E, Freedman M. An admixture scan in 1,484 African American women with breast cancer. *Cancer Epidemiology, Biomarkers and Prevention* 18: 3110-3117, 2009.
148. Britten CD, Finn RS, Bosserman LD, Wong SG, **Press MF**, Malik M, Lum BL, Slamon DJ. A phase I/II trial of trastuzumab plus erlotinib in metastatic HER2+ breast cancer: a dual ErbB targeted approach. *Clinical Breast Cancer* 1: 16-22, 2009.
149. Di Leo A, Finn RS, **Press MF**. In Reply: Lapatinib plus paclitaxel as first-line therapy for HER-2-positive metastatic breast cancer patients: inappropriate conclusions for a company-sponsored study? *Journal of Clinical Oncology* Apr 10 2009: 1920-1921.
150. Haiman CA, Garcia RR, Hsu C, Xia L, Ha H, Sheng X, Marchand LL, Kolonel LN, Henderson BE, Stallcup MR, Greene GL, **Press MF**. Screening and association testing of common coding variation in steroid hormone receptor co-activator and co-repressor genes in relation to breast cancer risk: The multiethnic cohort. *BMC Cancer* 9: 43, 2009.
151. Slamon DJ and **Press MF**, Alterations in the topoisomerase II-alpha and HER2 genes: Association with anthracycline sensitivity in human breast cancers. *Journal of the National Cancer Institute* 101: 615-618, 2009.
152. Sauter G, Lee J, Bartlett JMS, Slamon DJ, **Press MF**. Reply to V Arena et al. FISH for HER2 assessment in breast cancer: The data show this method to be the best primary test. *Journal of Clinical Oncology* 27: e9-e10, 2009.

153. Li CI, Mathes RW, Malone KE, Daling JR, Bernstein L, Marchbanks PA, Strom BL, Simon MS, **Press MF**, Deapen D, Burkman RT, Folger SG, McDonald JA, Spirtas R. Relationship between migraine history and breast cancer risk among premenopausal and postmenopausal women. *Cancer Epidemiology, Biomarkers and Prevention* 18(7):2030-2034, 2009.
154. Ma H, Wang Y, Sullivan-Halley J, Weiss L, Burkman RT, Simon M, Malone KE, Strom BL, Marchbanks PA, Spirtas R, **Press MF**, Bernstein L. Breast cancer receptor status: Do results from a centralized pathology laboratory agree with SEER registry reports? *Cancer Epidemiology, Biomarkers and Prevention* 18(8): 2214-2220, 2009.
155. Finn RS, **Press MF**, Dering J, Gomez H, Aziz Z, Arbushites M, Koehler M, Oliva C, Williams LS, Di Leo A. ER, PR, HER2, and EGFR expression and benefit from lapatinib in a prospective randomized trial of lapatinib with paclitaxel versus paclitaxel alone as first-line treatment in 579 Women with HER2 negative or unknown metastatic breast cancer. *Journal of Clinical Oncology* 27(24): 3908-3915, 2009.
156. Sauter G, Lee J, Slamon DJ, **Press MF**. Reply to Hammond et al. HER2 Assessment in Breast Cancer: FISH is Superior to IHC as the Best Primary Test. *Journal of Clinical Oncology* 27(October 20): e155-e157, 2009.
157. Johnston S, Pippen J Jr, Pivot X, Lichinitser M, Sadeghi S, Dieras V, Leonidas Gomez H, Romieu G, Manikhas G, Kennedy MJ, **Press MF**, Maltzman J, Florance A, O'Rourke L, Oliva C, Stein S, Pegram M. Lapatinib combined with letrozole versus letrozole and placebo as first-line therapy for postmenopausal hormone receptor-positive metastatic breast cancer. *Journal of Clinical Oncology* 27: 5538-5546, 2009.
158. Cheng CY, Kao WH, Patterson N, Tandon A, Haiman CA, Harris TB, Xing C, John EM, Ambrosone CB, Brancati FL, Coresh J, **Press MF**, Parekh RS, Klag MJ, Meoni LA, Hsueh WC, Fejerman L, Pawlikowska L, Freedman ML, Jandorf LH, Bandera EV, Ciupak GL, Nalls MA, Akylbekova EL, Orwoll ES, Leak TS, Miljkovic I, Li R, Ursin G, Bernstein L, Ardlie K, Taylor HA, Boerwinckle E, Zmuda JM, Henderson BE, Wilson JG, Reich D. Admixture mapping of 15,280 African Americans identifies obesity susceptibility loci on chromosomes 5 and X. *PLoS Genetics* 5: e1000490 (2009), PM ID: 19461885
159. Udler MS, Healey CS, Meyer KB, Ahmed S, Struewing JP, aranian M, Kwon EM, Zhang J, Tyrer J, Karlins E, Platte R, Kalmerzyaev B, Dicks E, Field HMaia A-T, Prathalingam R, Teschendorff A, McArthur S, Doody Dr, Luben R, Caldas C, Bernstein L, Kolonel LN, Henderson BE, Wu A, Le Marchand L, Ursin G, **Press MF**, Lindblom A Shen C-Y, Wu P-E, Wang H-C, Kang D, Yoo K-Y, Noh D-Y, Ahn S-H, Malone KE, Haiman CA, Pharoah PD, Ponder BAJ, Ostrander E, Easton DF, Dunning AM. Towards identifying the function of the breast cancer 16q12 locus. *Human Molecular Genetics* 18(9):1692-1703, 2009.
160. Downey L, Livingston RB, Koehler M, Arbushites M, Williams L, Santiago A, Guzman R, Villalobos I, Di Leo A, **Press MF**. Polysomy for Chromosome 17 in the Absence of HER2 Amplification Does Not Predict Improved Response to Combination Therapy with Lapatinib and Paclitaxel Compared to Paclitaxel Alone in Metastatic Breast Cancer. *Clinical Cancer Research* 16: 1281-1288, 2010.

161. Ma H, Wang Y, Sullivan-Halley J, Weiss L, Marchbanks PA, Spirtas R, Ursin G, Burkman RT, Simon MS, Malone KE, Strom BL, McDonald JA, **Press MF**, Bernstein L. Use of four biomarkers to evaluate the risk of breast cancer subtypes in the Women's Contraceptive and Reproductive Experiences Study. *Cancer Research* 70: 575-587, 2010.
162. Sauter G, Lee JA, Slamon DJ, Press MF. Reply to V. Arena et al. HER2 Assessment in Breast Cancer: Continuing Controversy Related to FISH as the Optimum Primary Test *Journal of Clinical Oncology* (February 10, 2010) 28: e85-e88, 2010.
163. Berstad P, Coates RJ, Bernstein L, Folger SG, Malone KE, Marchbanks PA, Weiss LK, Liff JM, McDonald JA, Strom BL, Simon MS, Deapen D, **Press MF**, Burkman RT, Spirtas R, Ursin G. Body mass index and risk of breast cancer in white and African American women: a case-control study. *Cancer Epidemiology Biomarkers and Prevention* 19:1532-1544, 2010.
164. Udler MS, Ahmed S, Healey CS, Meyer K, Struewing J, Maranian M, Kwon EM, Zhang J, Tyrer J, Karlins E, Platte R, Kalmyrzaev B, Dicks E, Field H, Maia A-T, Prathalingam R, Teschendorff A, McArthur S, Doody DR, Luben R, Caldas C, Bernstein L, Kolonel LK, Henderson BE, Wu AH, Le Marchand L, Ursin G, **Press MF**, Lindblom A, Margolin S, Shen C-Y, Yang S-L, Hsiung C-N, Kang D, Yoo K-Y, Noh D-Y, Ahn S-H, Malone KE, Haiman CA, Pharoah PD, Ponder BAJ, Ostrander EA, Easton DF, Dunning AM. Fine-scale mapping of the breast cancer 16q12 locus. *Human Molecular Genetics* 19: 2507-2515, 2010.
165. Valero V, Forbes J, Pegram MD, Pienkowski T, Eiermann W, von Minckwitz G, Roche H, Martin M, Crown J, Mackey JR, Fumoleau P, Rolski J, Mrcic-Krmpotic Z, Jagiello-Gruszfeld A, Riva A, Buyse M, Taupin H, Sauter G, **Press MF**, Slamon DJ. Multicenter phase III randomized trial comparing docetaxel and trastuzumab with docetaxel, carboplatin, and trastuzumab as first-line chemotherapy for patients with HER2-gene-amplified metastatic breast cancer (BCIRG 007 study): two highly active therapeutic regimens. *Journal of Clinical Oncology* 29: 149-156, 2011.
166. **Press MF**, Sauter G, Buyse M, Bernstein L, Guzman R, Santiago A, Villalobos IE, Eiermann W, Pienkowski T, Martin M, Robert N, Crown J, Bee V, Taupin H, Flom KJ, Tabah-Fisch I, Pauletti G, Lindsay MA, Riva A, Slamon DJ. Alteration of topoisomerase II-alpha gene in human breast cancer: Association with responsiveness to anthracycline-based chemotherapy. *Journal of Clinical Oncology* 29: 859-867, 2011.
167. Dieli-Conwright CM, Sullivan-Halley J, Patel A, **Press M**, Malone K, Ursin G, Burkman R, Strom B, Simon M, Weiss L, Marchbanks P, Folger S, Spirtas R, Deapen D, Bernstein L. "Does hormone therapy counter the beneficial effects of physical activity on breast cancer risk in postmenopausal women?" *Cancer Causes and Control* 22: 515-522, 2011.
168. Pasaniuc B, Zaitlen N, Lettre G, Chen GK, Tandon A, Kao WH, Ruczinski I, Fornage M, Siscovick DS, Zhu X, Larkin E, Lange LA, Cupples LA, Yang Q, Akyzbekova EL, Musani SK, Divers J, Mychaleckyj J, Li M, Papanicolaou GJ, Millikan RC, Ambrosone CB, John EM, Bernstein L, Zheng W, Hu JJ, Ziegler RG, Nyante SJ, Bandera EV, Ingles SA, **Press**

- MF**, Chanock SJ, Deming SL, Rodriguez-Gil JL, Palmer CD, Buxbaum S, Ekunwe L, Hirschhorn JN, Henderson BE, Myers S, Haiman CA, Reich D, Patterson N, Wilson JG, Price AL. Enhanced statistical tests for GWAS in admixed populations: assessment using African Americans from CARE and a Breast Cancer Consortium. *PLoS Genet* 7: e1001371, 2011, [PM ID: 21541012](#).
169. Slamon D, Eiermann W, Robert N, Pienkowski T, Martin M, **Press MF**, Mackey J, Glaspy J, Chan A, Pawliki M, Pinter T, Valero V, Liu M-C, Sauter G, von Minckwitz G, Visco F, Bee V, Buyse M, Bendahmane T, Lindsay M-A, Riva A, Crown J. Adjuvant trastuzumab in HER2-positive breast cancer. *New England Journal of Medicine* 365: 1273-1283, 2011, [PM ID: 21991949](#)
170. Eiermann W, Pienkowski T, Crown J, Sadeghi S, Martin M, Chan A, Saleh M, Sehdev S, Provencher L, Semiglazov V, **Press M**, Sauter G, Lindsay MA, Riva A, Buyse M, Drevot P, Taupin H, Mackey JR. Phase III Study of Doxorubicin / Cyclophosphamide With Concomitant Versus Sequential Docetaxel As Adjuvant Treatment in Patients With Human Epidermal Growth Factor Receptor 2-Normal, Node-Positive Breast Cancer: BCIRG-005 Trial. *Journal of Clinical Oncology* 29: 3877-3884, 2011, [PM ID: 21911726](#)
171. Lagos-Jaramillo VI, **Press MF**, Ricker CN, Dubeau L, Mai PL, Weitzel JN. "Pathological characteristics of BRCA-associated breast cancers in Hispanics." *Breast Cancer Res Treat* 130(1): 281-289, 2011. [PM ID: 21604016](#).
172. **Press MF**, Bernstein L, Sullivan-Halley J, Buyse M, Sauter G, Slamon DJ. Does topoisomerase II-alpha gene amplification provide useful information for treatment selection in patients with breast carcinoma? In Reply to R. Simon. *Journal of Clinical Oncology* 29: 2941-2944, 2011.
173. Gaudet MM, **Press MF**, Haile RW, Lynch CF, Glaser SL, Schildkraut J, Gammon MD, Douglas Thompson W, Bernstein JL. Risk factors by molecular subtypes of breast cancer across a population-based study of women 56 years or younger. *Breast Cancer Research and Treatment* 130(2): 587-597, 2011, [PM ID: 21667121](#).
174. Lu Y, Ma H, Malone KE, Norman SA, Sullivan-Halley J, Strom BL, Marchbanks PA, Spirtas R, Burkman RT, Deapen D, Folger SG, Simon MS, **Press MF**, McDonald JA, Bernstein L. Obesity and survival among black women and white women 35 to 64 years of age at diagnosis with invasive breast cancer. *Journal of Clinical Oncology* 29: 3358-3365, 2011, [PM ID: 21788570](#)
175. Hinch AG, Tandon A, Patterson N, Song Y, Rohland N, Palmer CD, Chen GK, Wang K, Buxbaum SG, Akylbekova EL, Aldrich MC, Ambrosone CB, Amos C, Bandera EV, Berndt SI, Bernstein L, Blot WJ, Bock CH, Boerwinkle E, Cai Q, Caporaso N, Casey G, Cupples LA, Deming SL, Diver WR, Divers J, Fornage M, Gillanders EM, Glessner J, Harris CC, Hu JJ, Ingles SA, Isaacs W, John EM, Kao WH, Keating B, Kittles RA, Kolonel LN, Larkin E, Le Marchand L, McNeill LH, Millikan RC, Murphy A, Musani S, Neslund-Dudas C, Nyante S, Papanicolaou GJ, **Press MF**, Psaty BM, Reiner AP, Rich SS, Rodriguez-Gil JL, Rotter JI, Rybicki BA, Schwartz AG, Signorello LB, Spitz M, Strom SS, Thun MJ, Tucker MA, Wang Z, Wiencke JK, Witte JS, Wrensch M, Wu X, Yamamura Y,

- Zanetti KA, Zheng W, Ziegler RG, Zhu X, Redline S, Hirschhorn JN, Henderson BE, Taylor HA, Price AL, Hakonarson H, Chanock SJ, Haiman CA, Wilson JG, Reich D, Myers SR. The landscape of recombination in African Americans. *Nature* 476: 170-175, 2011, [PM ID: 21775986](#)
176. Chen F, Chen GK, Millikan RC, John EM, Ambrosone CB, Bernstein L, Zheng W, Hu JJ, Ziegler RG, Deming SL, Bandera EV, Nyante S, Palmer JR, Rebbeck TR, Ingles SA, **Press MF**, Rodriguez-Gil JL, Chanock SJ, Le Marchand L, Kolonel LN, Henderson BE, Stram DO, Haiman CA. Fine-mapping of breast cancer susceptibility loci characterizes genetic risk in African Americans. *Human Molecular Genetics* 20: 4491-4503, 2011, [PM ID: 21852243](#)
177. Haiman CA, Chen GK, Vachon CM, Canzian F, Dunning A, Millikan RC, Wang X, Ademuyiwa F, Ahmed S, Ambrosone CB, Baglietto L, Balleine R, Bandera EV, Beckmann MW, Berg CD, Bernstein L, Blomqvist C, Blot WJ, Brauch H, Buring JE, Carey LA, Carpenter JE, Chang-Claude J, Chanock SJ, Chasman DI, Clarke CL, Cox A, Cross SS, Deming SL, Diasio RB, Dimopoulos AM, Driver WR, Dünnebier T, Durcan L, Eccles D, Edlund CK, Ekici AB, Fasching PA, Feigelson HS, Flesch-Janys D, Fostira F, Försti A, Fountzilas G, Gerty SM, Giles GG, Godwin AK, Goodfellow P, Graham N, Greco D, Hamann U, Hankinson SE, Hartmann A, Hein R, Heinz J, Holbrook A, Hoover RN, Hu JJ, Hunter DJ, Ingles SA, Irwanto A, Ivanovich J, John EM, Johnson N, Jukkola-Vuorinen A, Kaaks R, Ko YD, Kolonel LN, Konstantopoulou I, Kosma VM, Kulkarni S, Lambrechts D, Lee AM, Marchand LL, Lesnick T, Liu J, Lindstrom S, Mannermaa A, Margolin S, Martin NG, Miron P, Montgomery GW, Nevanlinna H, Nickels S, Nyante S, Olswold C, Palmer J, Pathak H, Pectasides D, Perou CM, Peto J, Pharoah PD, Pooler LC, **Press MF**, Pylkäs K, Rebbeck TR, Rodriguez-Gil JL, Rosenberg L, Ross E, Rüdiger T, Silva ID, Sawyer E, Schmidt MK, Schulz-Wendtland R, Schumacher F, Severi G, Sheng X, Signorello LB, Sinn HP, Stevens KN, Southey MC, Tapper WJ, Tomlinson I, Hogervorst FB, Wauters E, Weaver J, Wildiers H, Winqvist R, Berg DV, Wan P, Xia LY, Yannoukakos D, Zheng W, Ziegler RG, Siddiq A, Slager SL, Stram DO, Easton D, Kraft P, Henderson BE, Couch FJ. A common variant at the TERT-CLPTM1L locus is associated with estrogen receptor-negative breast cancer. *Nature Genetics* 43(12): 1210-1214, 2011, [PM ID: 22037553](#)
178. N'diaye A, Chen GK, Palmer CD, Ge B, Tayo B, Mathias RA, Ding J, Nalls MA, Adeyemo A, Adoue V, Ambrosone CB, Atwood L, Bandera EV, Becker LC, Berndt SI, Bernstein L, Blot WJ, Boerwinkle E, Britton A, Casey G, Chanock SJ, Demerath E, Deming SL, Diver WR, Fox C, Harris TB, Hernandez DG, Hu JJ, Ingles SA, John EM, Johnson C, Keating B, Kittles RA, Kolonel LN, Kritchevsky SB, Le Marchand L, Lohman K, Liu J, Millikan RC, Murphy A, Musani S, Neslund-Dudas C, North KE, Nyante S, Ogunniyi A, Ostrander EA, Papanicolaou G, Patel S, Pettaway CA, **Press MF**, Redline S, Rodriguez-Gil JL, Rotimi C, Rybicki BA, Salako B, Schreiner PJ, Signorello LB, Singleton AB, Stanford JL, Stram AH, Stram DO, Strom SS, Suktitipat B, Thun MJ, Witte JS, Yanek LR, Ziegler RG, Zheng W, Zhu X, Zmuda JM, Zonderman AB, Evans MK, Liu Y, Becker DM, Cooper RS, Pastinen T, Henderson BE, Hirschhorn JN, Lettre G, Haiman CA. Identification, replication, and fine-mapping of Loci associated with adult height in individuals of African ancestry. *PLoS Genet* 7: e1002298, 2011. [PM ID: 21998595](#)
179. Campan M, Moffitt M, Houshdaran S, Shen H, Widschwendter M, Daxenbichler G, Long T, Marth C, Laird-Offringa IA, **Press MF**, Dubeau L, Siegmund KD, Wu AH, Groshen S, Chandavarkar U, Roman LD, Berchuck A, Pearce CL, Laird PW. Genome-Scale Screen for

- DNA Methylation-Based Detection Markers for Ovarian Cancer. *PLoS ONE* 6 (12): e28141, 2011. [PM ID: 22163280](#)
180. **Press MF**, Gordon MA, Slamon DJ. Potential utility of an expression array signature for predicting anthracycline responsiveness or resistance. *Journal of Clinical Oncology* 30: 357-361, 2012. [PM ID: 22203766](#).
  181. Slamon DJ, Buyse M, **Press MF**. Adjuvant trastuzumab in HER2-positive breast cancer: Authors' Reply. *New England Journal of Medicine* 366: 663-666, 2012.
  182. Hovanesian-Larsen L, Taylor D, Hawes D, Spicer DV, **Press MF**, Wu AH, Pike MC, Pearce CL. Lowering oral contraceptive norethindrone dose increases estrogen and progesterone receptor levels with no reduction in proliferation of breast epithelium: a randomized trial. *Contraception* 86: 238-243, 2012, [PM ID: 22325110](#)
  183. Haque R, Ahmed SA, Inzhakova G, Shi J, Avila C, Polikoff J, Bernstein L, Enger SM, **Press MF**. Impact of breast cancer subtypes and treatment on survival: An analysis spanning two decades. *Cancer Epidemiology, Biomarkers & Prevention* 21: 1848-1855, 2012, [PM ID: 22989461](#).
  184. Siddiq A, Couch FJ, Chen GK, Lindström S, Eccles D, Millikan RC, Michailidou K, Stram DO, Beckmann L, Kyong Rhie S, Ambrosone CB, Aittomäki K, Amiano P, Apicella C, Baglietto L, Bandera EV, Beckmann MW, Berg CD, Bernstein L, Blomqvist C, Brauch H, Brinton L, Bui QM, Buring JE, Buys SS, Campa D, Carpenter JE, Chasman DI, Chang-Claude J, Chen C, Clavel-Chapelon F, Cox A, Cross SS, Czene K, Deming SL, Diasio RB, Diver WR, Dunning AM, Durcan L, Ekici AB, Fasching PA, Feigelson HS, Fejerman L, Figueroa JD, Fletcher O, Flesch-Janys D, Gaudet MM, Gerty SM, Rodriguez-Gil JL, Giles GG, van Gils CH, Godwin AK, Graham N, Greco D, Hall P, Hankinson SE, Hartmann A, Hein R, Heinz J, Hoover RN, Hopper JL, Hu JJ, Huntsman S, Ingles SA, Irwanto A, Isaacs C, Jacobs KB, John EM, Justenhoven C, Kaaks R, Kolonel LN, Coetzee GA, Lathrop M, Le Marchand L, Lee AM, Lee IM, Lesnick T, Lichtner P, Liu J, Lund E, Makalic E, Martin NG, McLean CA, Meijers-Heijboer H, Meindl A, Miron P, Monroe KR, Montgomery GW, Müller-Myhsok B, Nickels S, Nyante SJ, Olswold C, Overvad K, Palli D, Park DJ, Palmer JR, Pathak H, Peto J, Pharoah P, Rahman N, Rivadeneira F, Schmidt DF, Schmutzler RK, Slager S, Southey MC, Stevens KN, Sinn HP, **Press MF**, Ross E, Riboli E, Ridker PM, Schumacher FR, Severi G, Dos Santos Silva I, Stone J, Sund M, Tapper WJ, Thun MJ, Travis RC, Turnbull C, Uitterlinden AG, Waisfisz Q, Wang X, Wang Z, Weaver J, Schulz-Wendtland R, Wilkens LR, Van Den Berg D, Zheng W, Ziegler RG, Ziv E, Nevanlinna H, Easton DF, Hunter DJ, Henderson BE, Chanock SJ, Garcia-Closas M, Kraft P, Haiman CA, Vachon CM. A meta-analysis of genome-wide association studies of breast cancer identifies two novel susceptibility loci at 6q14 and 20q11. *Human Molecular Genetics* 21: 5373-5384, 2012, [PM ID: 22976474](#)
  185. Serce NB, Boesl A, Klamon I, von Serenyi S, Noetzel, **Press MF**, Dimmler A, Hartmann A, Sehouli J, Knuechel R, Beckmann MW, Fasching PA, Dahl E. Overexpression of SERBP1 (Plasminogen activator inhibitor 1 RNA binding protein) in human breast cancer is correlated with favourable prognosis. *BMC Cancer* 12(1): 597, 2012.

186. Jones ME, van Leeuwen FE, Hoogendoorn WE, Mourits MJE, Hollema H, van Boven H, **Press MF**, Bernstein L, Swerdlow AJ. Endometrial cancer survival after breast cancer in relation to tamoxifen treatment: pooled results from three countries, *Breast Cancer Research* 14(3): R91, 2012. DOI: 10.1186/bcr3206
187. David SP, Hamidovic A, Chen GK, Bergen AW, Wessel J, Kasberger JL, Brown WM, Petruzella S, Thacker EL, Kim Y, Nalls MA, Tranah GJ, Sung YJ, Ambrosone CB, Arnett D, Bandera EV, Becker DM, Becker L, Berndt SI, Bernstein L, Blot WJ, Broeckel U, Buxbaum SG, Caporaso N, Casey G, Chanock SJ, Deming SL, Diver WR, Eaton CB, Evans DS, Evans MK, Fornage M, Franceschini N, Harris TB, Henderson BE, Hernandez DG, Hitsman B, Hu JJ, Hunt SC, Ingles SA, John EM, Kittles R, Kolb S, Kolonel LN, Le Marchand L, Liu Y, Lohman KK, McKnight B, Millikan RC, Murphy A, Neslund-Dudas C, Nyante S, **Press M**, Psaty BM, Rao DC, Redline S, Rodriguez-Gil JL, Rybicki BA, Signorello LB, Singleton AB, Smoller J, Snively B, Spring B, Stanford JL, Strom SS, Swan GE, Taylor KD, Thun MJ, Wilson AF, Witte JS., Yamamura Y, Yanek LR, Yu K, Zheng W, Ziegler RG, Zonderman AB, Jorgenson E, Haiman CA, Furberg H. Genome-wide meta-analyses of smoking behaviors in African Americans. *Translational Psychiatry*. 2:e119, 2012
188. Chen F, Chen GK, Stram DO, Millikan RC, Ambrosone CB, John EM, Bernstein L, Zheng W, Palmer JR, Hu JJ, Rebbeck TR, Ziegler RG, Nyante S, Bandera EV, Ingles SA, **Press MF**, Ruiz-Narvaez EA, Deming SL, Rodriguez-Gil JL, Demichele A, Chanock SJ, Blot W, Signorello L, Cai Q, Li G, Long J, Huo D, Zheng Y, Cox NJ, Olopade OI, Ogundiran TO, Adebamowo C, Nathanson KL, Domchek SM, Simon MS, Hennis A, Nemesure B, Wu SY, Leske MC, Ambs S, Hutter CM, Young A, Kooperberg C, Peters U, Rhie SK, Wan P, Sheng X, Pooler LC, Van Den Berg DJ, Le Marchand L, Kolonel LN, Henderson BE, Haiman CA. A genome-wide association study of breast cancer in women of African ancestry. *Human Genetics* 132: 39-48, 2013, [PM ID: 22923054](#)
189. Gordon MA, Gundacker H, Benedetti J, Macdonald JS, Baranda J, Levin W, Wick N, Blanke CD, Elatre W, Weng P, Zhou J-Y, Lenz H-J, **Press MF**. Assessment of *HER2* gene amplification in adenocarcinomas of the stomach or gastroesophageal junction in the INT-0116/SWOG9008 clinical trial. *Annals of Oncology* 24(7): 1754-1761, 2013, [PM ID: 23524864](#).
190. Garcia-Closas M, Couch FJ, Lindstrom S, Michailidou K, Schmidt MK, Brook M, Orr N, Rhie SK, Riboli E, Feigelson HS, Le Marchand L, Buring JE, Eccles D, Miron P, Fasching PA, Brauch H, Chang-Claude J, Carpenter J, Godwin A, Nevanlinna H, Giles GG, Cox A, Hopper JL, Humphreys MK, Wang Q, Dennis J, Dicks E, Howat WJ, Schoof N, Bojesen SE, Lambrechts D, Broeks A, Andrulis IL, Guénel P, Burwinkel B, Sawyer EJ, Hollestelle A, Fletcher O, Winqvist R, Brenner H, Mannermaa A, Hamann U, Meindl A, Lindblom A, Zheng W, Devilee P, Goldberg MS, Lubinski J, Kristensen V, Swerdlow A, Anton-Culver H, Dörk T, Muir K, Matsuo K, Wu AH, Radice P, Teo SH, Shu X-O, Blot W, Kang D, Hartman M, Sangrajrang S, Shen C-Y, Southey MC, Park DJ, Hammet F, Stone J, Van't Veer LJ, Rutgers EJ, Lophatananon A, Stewart-Brown S, Siriwanarangsana P, Peto J, Schrauder MG, Ekici AB, Beckmann MW, dos Santos Silva I, Johnson N, Warren H, Tomlinson I, Kerin MJ, Miller N, Marme F, Schneeweiss A, Sohn C, Truong T, Laurent-Puig P, Kerbrat P, Nordestgaard BG, Nielsen SF, Flyger H, Milne RL, Perez JIA, Menéndez P, Müller H, Arndt V, Stegmaier C, Lichtner P, Lochmann M, Justenhoven C, Ko Y-D, The GENICA Network, Muranen TA, Aittomäki K, Blomqvist C, Greco D, Heikkinen T, Ito H, Iwata H, Yatabe Y, Antonenkova

- NN, Margolin S, Kataja V, Kosma V-M, Hartikainen JM, Balleine R, kConFab Investigators, Tseng C-c, Van Den Berg D, Stram DO, Neven P, Dieudonné A-S, Leunen K, Rudolph A, Nickels S, Flesch-Janys D, Peterlongo P, Peissel B, Bernard L, Olson JE, Wang X, Stevens K, Severi G, Baglietto L, McLean C, Coetzee GA, Henderson BE, Schumacher F, Bogdanova NV, Labrèche F, Dumont M, Yip CH, Taib NAM, Cheng C-Y, Shrubsole M, Long J, Pylkäs K, Jukkola-Vuorinen A, Kauppila S, Knight JA, Glendon G, Mulligan AM, Tollenaar RAEM, Seynaeve CM, Kriege M, Hooning MJ, van den Ouweland AMW, van Deurzen Carolien HM, Lu W, Gao Y-T, Cai H, Balasubramanian SP, Cross SS, Reed MWR, Signorello L, Cai Q, Shah M, Miao H, Chan CW, Chia KS, Jakubowska A, Jaworska K, Durda K, Hsiung C-N, Wu P-E, Yu J-C, Ashworth A, Jones M, Tessier DC, González-Neira A, Pita G, Alonso MR, Vincenti D, Bacot F, Ambrosone CB, Bandera EV, John EM, Chen GK, Hu JJ, Rodriguez-Gil JL, Bernstein L, **Press MF**, Ziegler RG, Millikan RM, Deming-Halverson SL, Nyante S, Ingles SA, Waisfisz Q, Tsimiklis H, Makalic E, Schmidt D, Bui M, Gibson L, Müller-Myhsok B, Hein R, Dahmen No, Beckmann L, Aaltonen K, Czene K, Irwanto A, Liu J, Turnbull C, FBCS, Rahman N, Meijers-Heijboer H, Uitterlinden AG, Rivadeneira F, ABCTB Investigators, Olswood C, Slager S, Pilarski R, Ademuyiwa F, Konstantopoulou I, Martin NG, Montgomery GW, Slamon DJ, Rau C, Lux MP, Jud SM, Bruning T, Weaver JE, Sharma P, Pathak H, Tapper W, Gerty S, Durcan L, Trichopoulos D, Tumino R, Peeters PH, Weiderpass E, Johansson M, Khaw K-t, Travis R, Clavel-Chapelon F, Kolonel LN, Chen C, Beck A, Hankinson SE, Berg C, Hoover RN, Lissowska J, Figueroa J, Chasman DI, Gaudet MM, Diver WR, Willett WC, Hunter DJ, Simard J, Benitez J, Dunning AM, Sherman ME, Chenevix-Trench G, Chanock SJ, Hall P, Pharoah P, Vachon C, Easton DF, Haiman CA, Kraft P. Genome-wide association studies identify four ER-negative specific breast cancer risk loci. *Nature Genetics* 45: 392-8, 398e1-2 (2013), [PM ID: 23535733](#).
191. Perez EA, **Press MF**, Dueck AC, Jenkins RB, Kim C, Chen B, Villalobos I, Paik S, Buyse M, Wiktor AE, Meyer R, Finnigan M, Zujewski J, Shing M, Stern HM, Lingle WL, Reinholz MM, Slamon DJ. Immunohistochemistry and fluorescence in situ hybridization assessment of HER2 in clinical trials of adjuvant therapy for breast cancer (NCCTG N9831, BCIRG 006, and BCIRG 005). *Breast Cancer Research and Treat* 138: 99-108, 2013, [PM ID: 23420271](#).
192. Monda KL, Chen GK, Taylor KC, Palmer C, Edwards TL, Lange LA, Ng MC, Adeyemo AA, Allison MA, Bielak LF, Chen G, Graff M, Irvin MR, Rhie SK, Li G, Liu Y, Liu Y, Lu YC, Nalls MA, Sun YV, Wojczynski MK, Yanek LR, Aldrich MC, Ademola A, Amos C, Bandera EV, Bock CH, Britton A, Broeckel U, Cai Q, Caporaso N, Carlson C, Carpten J, Casey G, Chen W-M, Chen F, Chen Y-DI, Chiang CWK, Coetzee GA, Demerath E, Deming SL, Driver RW, Dubbert P, Feitosa M, Freedman BI, Gillanders EM, Gottesman O, Guo X, Haritunians T, Harris T, Harris CC, Hennis AJM, Hernandez DG, McNeill LH, Howard TD, Howard B, Howard V, Johnson KC, Kang SJ, Keating BJ, Kolb S, Kuller L, Kutlar A, Langefeld CD, Lettre G, Lohman K, Lotay V, Lyon H, Manson JE, Maixner W, Meng Y, Monroe K, Morhason-Bello I, Murphy AB, Mychaleckyj JC, Nadukuru R, Nadukuru R, Nathanson KL, Nayak U, N'Diaye A, Nemesure B, Neslund-Dudas C, Neuhauser M, Nyante S, Ochs-Balcom H, Oguinni A, Ogundiran TO, Ojengbede O, Olopade OI, Palmer JR, Narvaez ER, Palmer ND, **Press MF**, Rampersaud E, Rasmussen-Torvik LJ, Rodriguez-Gil JL, Ruiz-Narvaez EA, Salako B, Schadt EE, Schwartz AG, Shriner DA, Siscovick D, Smith S, Wassertneil-Smoller S, Speliotes E, Spitz M, Sucheston L, Taylor H, Tayo BO, Tucker MA, Van Den Berg DJ, Velez Edwards DR, Wang Z, Wiencke JK, Winkler T, Witte JS, Wrensch M, Wu X, Yang JJ, Levin AM, Young TR, Zakai N, Cushman M, Zanetti K, Zhao JH, Zhao W, Zheng Y, Zhou J, Ziegler RG, Zmuda

- J, Fernandes JK, Gilkeson GS, Kamen DL, Hunt KJ, Spruill IJ, Ambrosone CB, Ambs S, Arnett DK, Atwood L, Becker DM, Berndt SI, Bernstein L, Blot WJ, Borecki IB, Bottinger EP, Bowden DW, Burke G, Chanock SJ, Cooper RS, Ding J, Evans MK, Fox C, Grant S, Hsing A, Hu JJ, Ingles SA, John EM, Jordan JM, Kabagambe EK, Kardia SL, Ketkar S, Kittles RA, Kolonel LN, Le Marchand L, Liu S, McKnight B, Millikan RC, Mosley TH, Patel SR, Pettaway CA, Peysner PA, Psaty BM, Redline S, Rotimi CN, Rybicki BA, Schreiner P, Signorello LB, Singleton AB, Stanford JL, Strom SS, Thun MJ, Vitolins M, Zheng W, Zhu X, Zonderman AB, NABEC Consortium, UKBEC Consortium, BioBank Japan Project, AGEN Consortium, Charles Kooperberg, Papanicolaou G, Henderson BE, Reiner AP, Hirschhorn JN, Loos RJF, North KE, Haiman CA. A meta-analysis identifies new loci associated with body mass index in individuals of African Ancestry. *Nature Genetics* 45 (6): 690-696, 2013, [PM ID: 23583978](#)
193. Song C, Chen G, Millikan RC, Ambrosone CB, John EM, Bernstein L, Zheng W, Hu JJ, Ziegler RG, Nyante S, Bandera EV, Ingles SA, **Press MF**, Deming SL, Rodriguez-Gil JL, Chanock SJ, Wan P, Sheng X, Pooler LC, Van Den Berg DJ, Le Marchand L, Kolonel LN, Henderson BE, Haiman C, Stram D. A genome-wide scan for breast cancer risk haplotypes among African American women. *PLoS One* 8: e57298 (2013), [PM ID: 23468962](#)
194. Ma H, Lu Y, Malone KE, Marchbanks PA, Deapen DM, Spirtas R, Burkman RT, Strom BL, McDonald J, Folger S, Simon MS, Sullivan-Halley J, **Press MF**, Bernstein L. Mortality risk of black women and white women with invasive breast cancer by hormone receptors, HER2, and p53 Status. *BMC Cancer* 13:225, 4 May 2013.
195. Demerath EW, Liu C-T, Franceschini N, Chen G, Palmer JR, Smith EN, Chen CTL, Ambrosone CB, Arnold AM, Bandera EV, Berenson GS, Bernstein L, Britton A, Cappola AR, Carlson CS, Chanock SJ, Chen W, Chen Z, Deming SL, Elks CE, Evans MK, Gajdos Z, Henderson BE, Hu JJ, Ingles S, John EM, Kerr KF, Kolonel LN, Le Marchand L, Lu X, Millikan RC, Musani SK, Nock NL, North K, Nyante S, **Press MF**, Rodriguez-Gil JL, Ruiz-Narvaez EA, Schork NJ, Srinivasan SR, Woods NF, Zheng W, Ziegler RG, Zonderman A, Heiss G, Windham BG, Wellons M, Murray SS, Nalls M, Rajkovic A, Hirschhorn J, Cupples LA, Kooperberg C, Murabito JM, Haiman CA. Genome-wide association study of age at menarche in African-American women. *Human Molecular Genetics* 22(16): 3329-3346, 2013, [PM ID: 23599027](#).
196. Wolff A, Hammond MEH, Hicks DG, Dowsett M, McShane L, Allison KH, Allred DC, Bartlett JMS, Bilous M, Fitzgibbons P, Hanna W, Jenkins RB, Mangu P, Paik S, Perez E, **Press MF**, Spears PA, Vance GH, Viale G, Hayes D. Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology - College of American Pathologists (ASCO/CAP) clinical practice guideline update. *Journal of Clinical Oncology* 31: 3997-4013, 2013, [PM ID: 24101045](#).
197. Ma H, Lu Y, Marchbanks PA, Folger SG, Strom BL, McDonald JA, Simon MS, Weiss L, Burkman RT, Sullivan-Halley J, Deapen DM, **Press MF**, Bernstein L. Quantitative measures of estrogen receptor expression in relation to breast cancer-specific mortality among white women and black women. *Breast Cancer Research* 15: R90, 2013. <http://breast-cancer-research.com/content/15/5/R90>, [PM ID: 24070170](#).

198. Begg CB, Zabor, Bernstein JL, Bernstein L, **Press MF**, Seshan VE. A conceptual and methodological framework for investigating etiologic heterogeneity. *Statistics in Medicine* 32: 5039-5052, 2013, [PM ID: 23857589](#).
199. Finn RS, **Press MF**, Dering J, O'Rourke L, Florance A, Ellis C, Martin A-M, Johnston S. Quantitative ER and PgR assessment as predictors of benefit from lapatinib in postmenopausal women with hormone receptor-positive, HER2-negative metastatic breast cancer treated with letrozole and lapatinib or letrozole and placebo. *Clinical Cancer Research* 20: 736-743, 2014, [PM ID: 24198242](#).
200. Feng Y, Chen GK, Stram DO, Millikan RC, Ambrosone CB, John EM, Bernstein L, Zheng W, Olshan AF, Hu JJ, Ziegler RG, Nyante S, Bandera EV, Ingles SA, **Press MF**, Deming SL, Rodriguez-Gil JL, Palmer JR, Olopade OI, Huo D, Stram A, Park K, Rand K, Chanock SJ, Le Marchand L, Kolonel LN, Conti D, Easton D, Henderson BE, Haiman CA. A Comprehensive Examination of Breast Cancer Risk Loci in African American Women. *Human Molecular Genetics* 23: 5518-5526, 2014. doi:10.1093/hmg/ddu252. [PM ID: 24852375](#).
201. Press OA, Guzman R, Cervantes M, Santiago A, **Press MF**. Characterization of HER2 Status by Fluorescence *in situ* Hybridization (FISH) and Immunohistochemistry (IHC), *Methods in Molecular Biology* 1180: 181-208, 2014. [PM ID: 25015148](#).
202. Chen CTL, Liu C-T, Chen GK, Andrews JS, Arnold AM, Dreyfus J, Franceschini N, Garcia ME, Kerr KF, Li G, Lohman KK, Musani SK, Nalls MA, Raffel LJ, Smith J, Ambrosone CB, Bandera EV, Bernstein L, Britton A, Brzyski RG, Cappola A, Carlson CS, Couper D, Deming SL, Goodarzi MO, Heiss G, John EM, Lu X, Le Marchand L, Marcianti K, McKnight B, Millikan R, Nock NL, Olshan AF, **Press MF**, Vaiyda D, Woods NF, Taylor HA, Zhao W, Zheng W, Evans MK, Harris TB, Henderson BE, Kardia SLR, Kooperberg C, Liu Y, Mosley TH, Psaty B, Wellons M, Windham BG, Zonderman AB, Cupples LA, Demerath EW, Haiman C, Murabito JM, Rajkovic A. Meta-analysis of loci associated with age at natural menopause in African-American women. *Human Molecular Genetics* 23 (12): 3327-3342, 2014, [PM ID: 24493794](#).
203. Wolff AC, Hammond MEH, Hicks DG, Dowsett M, McShane L, Allison KH, Allred DC, Bartlett JMS, Bilous M, Fitzgibbons P, Hanna W, Jenkins RB, Mangu PB, Paik S, Perez EA, **Press MF**, Spears PA, Vance GH, Viale G, Hayes DF. Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology - College of American Pathologists (ASCO/CAP) clinical practice guideline update. *Archives of Pathology and Laboratory Medicine*. 138(2):241-56, 2014, [PM ID: 24099077](#).
204. Fasching PA, Weihbrecht S, Haeberle L, Gasparyan A, Villalobos IE, Ma Y, Ekici AB, Wachter DL, Hartmann A, Beckmann MW, Slamon DJ, **Press MF**. *HER2* and *TOP2A* amplification in a hospital-based cohort of breast cancer patients: associations with patient and tumor characteristics. *Breast Cancer Research and Treatment* 145(1): 193-203, 2014, [PM ID: 24682655](#).

205. Bhatia G, Tandon A, Patterson N, Ambrosone CB, Bandera EV, Berndt SI, Bernstein L, Blot WJ, Bock CH, Casey G, Deming SL, Diver WR, Gapstur SM, Ingles SA, Isaacs W, John EM, Kittles RA, Larkin E, Millikan RC, Murphy A, Neslund-Dudas C, Nyante S, **Press MF**, Rodriguez-Gil JL, Rybicki BA, Signorello LB, Strom SS, Witte JS, Yamamura Y, Zheng W, Ziegler RG, Henderson BE, Aldrich MC, Harris CC, Caporaso N, Gillanders EM, Amos C, Tucker MA, McNeill LH, Schwartz AG, Spitz M, Wiencke JK, Wu X, Zanetti KA, Chanock SJ, Haiman CA, Reich D, and Price AL. Genome-wide scan of 29,141 African Americans finds no evidence of selection since admixture. *American Journal of Human Genetics* 95: 437-444, 2014, [PM ID: 25242497](#).
206. **Press MF**, Ma Y. HER2/ERBB2 testing: Assessment of status for targeted therapies, Chapter 27 in *Diseases of the Breast*, edited by Jay R. Harris, Marc E. Lippman, Monica Morrow, and C. Kent Osborne, pp. 423-438, 2014.
207. Lang JE, Wechsler JS, **Press MF**, Tripathy D. Molecular markers for breast cancer diagnosis, prognosis and targeted therapy. *Journal of Surgical Oncology* 111: 81-90, 2015. [PM ID: 25091830](#) (Donald L Morton Award, given to the authors of the most downloaded article from *Journal of Surgical Oncology* in the previous year)
208. Stern HM, Gardner H, Burzykowski T, Elatre W, Pestano GA, Santiago A, Villalobos I, Eiermann W, Pienkowski T, Martin M, Robert N, Crown J, Nuciforo P, Bee V, Taupin H, Slamon DJ, **Press MF**. PTEN loss is associated with worse outcome in *HER2*-amplified breast cancer patients but is not associated with trastuzumab resistance. *Clinical Cancer Research* 21(9): 2065–2074, 2015. [PM ID: 25649019](#). DOI: [10.1158/1078-0432.CCR-14-2993](https://doi.org/10.1158/1078-0432.CCR-14-2993)
209. Sottoriva A, Kang H, Ma Z, Graham TA, Solomon MP, Zhao JS, Marjoram P, Siegmund K, **Press MF**, Shibata D, Curtis C. A big bang model of human colorectal tumor growth. *Nature Genetics* 47: 209-216, 2015. [PM ID: 25665006](#).
210. Wen W, Chen W, Xiao N, Bender R, Ghazalpour A, Tan Z, Swenson J, Millis S, Basu G, Gatalica Z, **Press MF**. Mutations in the kinase domain of the *HER2/ERBB2* gene identified in a wide variety of human cancers. *Journal of Molecular Diagnostics* 17: 487-95, 2015. [PM ID: 26320869](#). DOI: [10.1016/j.jmoldx.2015.04.003](https://doi.org/10.1016/j.jmoldx.2015.04.003)
211. Chen F, He J, Zhang J, Chen GK, Thomas V, Ambrosone CB, Bandera EV, Berndt SI, Bernstein L, Blot WJ, Hsing AW, Hu JJ, Ingles SA, John EM, Kittles RA, Kolb S, Leske CM, Millikan RC, Monroe KR, Murphy A, Nemesure B, Neslund-Dudas C, Nyante S, Ostrander EA, **Press MF**, Rodriguez-Gil JL, Rybicki BA, Schumacher R, Stanford JL, Signorello LB, Strom SS, Stevens V Van Den Berg D, Wang Z, Witte JS, Wu SY, Yamamura Y, Zhang W, Ziegler RG, Stram AH, Kolonel LN, Le Marchand L, Henderson BE, Haiman CA, Stram DO. Methodological considerations related to genome-wide assessments of height heritability in a large sample of African ancestry adults. *PLoS One* 10: e0131106, 2015. [PM ID: 26125186](#).
212. Ma H, Xu X, Ursin G, Simon M, Marchbanks PA, Malone K, Lu Y, McDonald J, Folger SG, Weiss LK, Sullivan-Halley J, Deapen DM, **Press MF**, Bernstein L. Reduced Risk of

- Breast Cancer Associated with Recreational Physical Activity Varies by HER2 status. *Cancer Medicine* 4: 1122-1135, 2015. [PM ID: 25924995](#)
213. Wolff AC, Hammond ME, Hicks DG, Allison KH, Bartlett JM, Bilous M, Fitzgibbons P, Hanna W, Jenkins RB, Mangu PB, Paik S, Perez EA, **Press MF**, Spears PA, Vance GH, Viale G, Dowsett M, McShane LM, Hayes DF. "Reply to E.A. Rakha et al." *Journal of Clinical Oncology* 33: 1302-1304, 2015. [PM ID: 25753441](#).
214. Sook Lee N, Evgrafov OV, Souaiaia T, Bonyad A, Herstein J, Yeun Lee J, Kim J, Ning Y, Sixto M, Weitz AC, Lenz HJ, Wang K, Knowles JA, **Press MF**, Salvaterra PM, Kirk Shung K, Chow RH. Non-coding RNAs derived from an alternatively spliced REST transcript (*REST-003*) regulate breast cancer invasiveness. *Science Reports* 5: 11207, 2015. [PM ID: 26053433](#).
215. Kang H, Salomon MP, Sottoriva A, Zhao J, Toy M, **Press MF**, Curtis C, Marjoram P, Siegmund K, Shibata D. Many Private Mutations Originate From The First Few Divisions Of A Human Colorectal Adenoma. *Journal of Pathology* 237: 355-62, 2015. [PM ID: 26119426](#).
216. Zhang C, Zhong J, Stucky A, Chen X-L, **Press MF**, Zhang X. Histone acetylation: novel target for the treatment of acute lymphoblastic leukemia: the launch of Clinical Epigenetics. *Clinical Epigenetics* 7: 117, 2015. [PM ID: 26543507](#)
217. Hecht JR, Bang YJ, Qin SK, Chung HC, Wu JM, Park JO, Jeziorski K, Shparyk Y, Hoff PM, Sobrero A, Salman P, Li J, Protsenko SA, Wainberg Z, Buyse M, Afenjar K, Houe V, Garcia A, Kaneko T, Huang Y, Khan-Wasti S, Santillana S, **Press MF**, Slamon DJ. Lapatinib in Combination With Capecitabine Plus Oxaliplatin in Human Epidermal Growth Factor Receptor 2-Positive Advanced or Metastatic Gastric, Esophageal, or Gastroesophageal Adenocarcinoma: TRIO-013/LOGiC--A Randomized Phase III Trial. *Journal of Clinical Oncology* 34: 443-451, 2016, [PM ID: 26628478](#).
218. Palanca-Wessels MC, Booth GC, Convertine AJ, Lundy BS, Berguig GW, **Press MF**, Hamlin DK, Wilbur DS, Stayton PS, Press OW. Antibody targeting facilitates effective intratumoral siRNA nanoparticle delivery to HER2-overexpressing cancer cells. *Oncotarget* 7: 9561-9575, 2016, [PM ID: 26840082](#).
219. **Press MF**, Villalobos I, Santiago A, Guzman R, Estrada MC, Gasparyan A, Campeau A, Ma Y, Tsao-Wei D, Groshen SL. Assessing the New American Society of Clinical Oncology/College of American Pathologists Guidelines for HER2 Testing by Fluorescence In Situ Hybridization: Experience of an Academic Consultation Practice. *Archives of Pathology and Laboratory Medicine* 140 (11): 1250-1258, 2016, [PM ID: 27081877](#). DOI: [10.5858/arpa.2016-0009-OA](#)
220. Lee CK, Davies L, GebSKI V, Lord SJ, Di Leo A, Johnston S, Geyer Jr C, Cameron D, **Press MF**, Ellis C, Loi S, Marshner I, Simes J, de Souza P. Serum Human Epidermal Growth Factor 2 Extracellular Domain as a Predictive Biomarker for Lapatinib Treatment Efficacy in Patients with Advanced Breast Cancer. *Journal of Clinical Oncology* 34: 936-944, 2016, [PM ID: 26811533](#).

221. Mackey JR, Pienkowski T, Crown J, Sadeghi S, Martin M, Chan A, Saleh M, Sehdev S, Provencher L, Semiglazov V, **Press MF**, Sauter G, Lindsay M-A, Houé V, Buyse M, Drevot P, Hitier S, Bensfia S, Eiermann W; on behalf of the TRIO/BCIRG-005 investigators. Long-term outcomes after adjuvant treatment of sequential versus combination docetaxel with doxorubicin and cyclophosphamide in node-positive breast cancer - BCIRG-005 randomized trial. *Annals of Oncology* 27: 1041-1047, 2016, [PM ID: 26940688](#).
222. Prat A, Cheang MC, Galván P, Nuciforo P, Paré L, Adamo B, Muñoz M, Viladot M, **Press MF**, Gagnon R, Ellis C, Johnston S. Prognostic Value of Intrinsic Subtypes in Hormone Receptor-Positive Metastatic breast cancer treated with Letrozole with or without Lapatinib. *JAMA Oncology* 2: 1287-1294, 2016, [PM ID: 27281556](#)
223. Rand KA, Song C, Dean E, Serie DJ, Curtin K, Sheng X, Hu D, Huff CA, Bernal-Mizrachi L, Tomasson MH, Ailawadhi S, Singhal S, Pawlish K, Peters E, Bock CH, Stram A, Van Den Berg DJ, Edlund CK, Conti DV, Zimmerman T, Hwang AE, Huntsman S, Graff J, Nooka A, Kong Y, Pregja SL, Berndt SI, Blot WJ, Carpten J, Casey G, Chu L, Diver RW, Stevens VL, Lieber MR, Goodman PJ, Hennis AJM, Hsing AW, Mehta J, Kittles RA, Kolb S, Klein EA, Leske C, Murphy AB, Nemesure B, Neslund-Dudas C, Strom SS, Vij R, Rybicki BA, Stanford JL, Signorello LB, Witte JS, Ambrosone CB, Bhatti P, John EM, Bernstein L, Zheng W, Olshan AF, Hu JJ, Ziegler RG, Nyante SJ, Bandera EV, Birmann BM, Ingles SA, **Press MF**, Atanackovic D, Glenn MJ, Cannon-Albright LA, Jones B, Tricot G, Martin TG, Kumar SK, Wolf JL, Deming SL, Rothman N, Pettaway C, Brooks-Wilson AR, Rajkumar SV, Kolonel LN, Chanock SJ, Slager SL, Severson RK, Janakiraman N, Terebelo HR, Brown EE, De Roos AJ, Mohrbacher AF, Colditz GA, Henderson BE, Giles GG, Spinelli JJ, Chiu B, Munshi NC, Anderson KC, Levy J, Zonder JA, Orłowski RZ, Lonial S, Camp NJ, Vachon CM, Ziv E, Stram DO, Hazelett DJ, Haiman CA, Cozen W. A meta-analysis of multiple myeloma risk regions in African and European ancestry populations identifies putatively functional loci. *Cancer Epidemiology, Biomarkers & Prevention* 25(12): 1609-1618, 2016, [cebp.aacrjournals.org/content/early/2016/09/01/1055-9965.EPI-15-1193](http://cebp.aacrjournals.org/content/early/2016/09/01/1055-9965.EPI-15-1193).
224. Huo D, Feng Y, Haddad S, Zheng Y, Yao S, Han YJ, Ogundiran TO, Adebamowo C, Ojengbede O, Falusi AG, Zheng W, Blot W, Cai Q, Signorello L, John EM, Bernstein L, Hu JJ, Ziegler RG, Nyante S, Bandera EV, Ingles SA, **Press MF**, Deming SL, Rodriguez-Gil JL, Nathanson KL, Domchek SM, Rebbeck TR, Ruiz-Narváez EA, Sucheston-Campbell LE, Bensen JT, Simon MS, Hennis A, Nemesure B, Leske MC, Ambs S, Chen LS, Qian F, Gamazon ER, Lunetta KL, Cox NJ, Chanock SJ, Kolonel LN, Olshan AF, Ambrosone CB, Olopade OI, Palmer JR, Haiman CA. Genome-wide association studies in women of African ancestry identified 3q26.21 as a novel susceptibility locus for oestrogen receptor negative breast cancer. *Human Molecular Genetics*. 25(21): 4835-4846, 2016. doi: 10.1093/hmg/ddw305. PMID: 28171663
225. **Press MF**, Sauter G, Buyse M, Fourmanoir H, Quinaux E, Eiermann W, Robert N, Pienkowski T, Crown J, Martin M, Valero V, Mackey JR, Bee V, Ma Y, Villalobos I, Campeau A, Mirlacher M, Lindsay MA, Slamon DJ. *HER2* Gene Amplification Testing by Fluorescence in situ Hybridization (FISH): Comparison of the American Society of Clinical Oncology (ASCO)-College of American Pathologists (CAP) Guidelines with FISH

- Scores used for enrollment in Breast Cancer International Research Group (BCIRG) Clinical Trials. *Journal of Clinical Oncology* 34 (29): 3518-3528, 2016. DOI: 10.1200/JCO.2016.66.6693
226. Qian F, Feng Y, Zheng Y, Ogundiran TO, Ojengbede O, Zheng W, Blot W, Ambrosone CB, John EM, Bernstein L, Hu JJ, Ziegler RG, Nyante S, Bandera EV, Ingles SA, **Press MF**, Nathanson KL, Hennis A, Nemesure B, Ambs S, Kolonel LN, Olopade OI, Haiman CA, Huo D. Genetic variants in microRNA and microRNA biogenesis pathway genes and breast cancer risk among women of African ancestry. *Human Genetics* 135: 1145-1159, 2016, [PM ID: 27380242](#)
  227. Huo D, Feng Y, Haddad S, Zheng Y, Yao S, Han Y-J, Ogundiran TO, Adebamowo C, Ojengbede O, Falusi AG, Zheng W, Blot W, Cai Q, Signorello L, John EM, Bernstein L, Hu JJ, Ziegler RG, Nyante S, Bandera EV, Ingles SA, **Press MF**, Deming SL, Rodriguez-Gil JL, Nathanson KL, Domchek SM, Rebbeck TR, Ruiz-Narváez EA, Sucheston-Campbell LE, Bensen JT, Simon MS, Hennis A, Nemesure B, Wu S-Y, Leske MC, Ambs S, Chen LS, Qian F, Gamazon ER, Lunetta KL, Cox NJ, Chanock SJ, Kolonel LN, Olshan AF, Ambrosone CB, Olopade OI, Palmer JR, Haiman CA. Characterizing Genetic Susceptibility to Breast Cancer in Women of African Ancestry. *Human Cancer Epidemiology, Biomarkers & Prevention* 26: 1016-1026, 2017, [PM ID: 28377418](#)
  228. **Press MF**, Ellis CE, Gagnon R, Grob T, Buyse M, Villalobos I, Liang Z, Wu S, Bang Y-J, Qin S, Chung HC, Xu J, Park JO, Jeziorski K, Afenjar K, Ma Y, Estrada MC, Robinson DM, Scherer SJ, Sauter G, Hecht JR, Slamon DJ. *HER2* status in advanced or metastatic gastric, esophageal, or gastro-esophageal adenocarcinoma for entry to TRIO-013/LOGiC trial of lapatinib. *Molecular Cancer Therapeutics* 16 (1): 228 - 238, 2017; the paper is available online at <http://mct.aacrjournals.org/cgi/content/abstract/1535-7163.MCT-15-0887>. [PM ID: 27811012](#)
  229. Joshi H, **Press MF**. “Molecular oncology of breast cancer”, in 5th edition of The Breast: Comprehensive Management of Benign and Malignant Diseases by Bland KI, Copeland EM, Klimberg CV, and Gradishar W, (editors) Saunders Elsevier, pp. 282-303, 2017.
  230. Ma H, Ursin G, Xu X, Lee E, Togawa K, Duan L, Lu Y, Malone KE, Marchbanks PA, McDonald JA, Simon MS, Folger SG, Sullivan-Halley J, Deapen DM, **Press MF**, Bernstein L. Reproductive factors and the risk of triple negative breast cancer in white women and African-American women: a pooled analysis. *Breast Cancer Research* 19: 6, 2017; DOI: 10.1186/s13058-016-0799-9
  231. Murphy ME, Liu S, Huo D, Liu Q, Dolfi SC, Hirshfield KM, Hong C-C, Hu Q, Olshan AF, Ogundiran TO, Adebamowo C, Domchek SM, Nathanson KL, Nemesure B, Ambs S, Blot WJ, Feng Y, John EM, Bernstein L, Zheng W, Hu JJ, Ziegler RG, Nyante S, Ingles SA, **Press MF**, Deming SL, Rodriguez-Gil JL, Haiman CA, Olopade O, Lunetta KL, Palmer JR, and Ambrosone CB. A functionally significant SNP in TP53 and breast cancer risk in African American women. *NJP Breast Cancer* 3: 5, 2017, [PM ID: 28649645](#)

232. Zhang C, Yang SJ, Wen Q, Zhong JF, Chen XL, Stucky A, Press MF, Zhang X. Human derived normal mesenchymal stem/stromal cells in anticancer therapies. *J Cancer* 8: 85-96, 2017. [PM ID: 28123601](#)
233. Ma H, Ursin G, Xu X, Lee E, Togawa K, Duan L, Lu Y, Malone KE, Marchbanks PA, McDonald JA, Simon MS, Folger SG, Sullivan-Halley J, Deapen DM, **Press MF**, Bernstein L. Reproductive factors and the risk of triple-negative breast cancer in white women and African-American women: a pooled analysis. *Breast Cancer Research* 19: 6 (2017) [PM ID: 28086982](#)
234. Ng MCY, Graff M, Lu Y, Justice A, Mudgal P, Liu C-T, Young K, Yanek L, Feitosa M, Wojczynski M, Rand K, Brody J, Cade B, Dimitrov L, Duan Q, Guo X, Lange L, Nalls M, Okut H, Tajuddin S, Tayo B, Vedantam S, Bradfield J, Chen G, Chen W-M, Chesi A, Irvin M, Padhukasahasram B, Smith J, Zheng W, Allison M, Ambrosone C, Bandera E, Bartz T, Berndt S, Bernstein L, Blot W, Bottinger E, Carpten J, Chanock S, Chen Y-DI, Conti D, Cooper R, Fornage M, Freedman B, Garcia M, Goodman P, Hsu Y-H, Hu J, Huff C, Ingles S, John E, Kittles R, Klein E, Li J, McKnight B, Nayak U, Nemesure B, Ogunniyi A, Olshan A, **Press M**, Rohde R, Rybicki B, Salako B, Sanderson M, Shao Y, Siscovick D, Stanford J, Stevens V, Stram A, Strom S, Vaidya D, Witte J, Yao J, Zhu X, Ziegler R, Zonderman A, Adeyemo A, Ambs S, Cushman M, Faul J, Hakonarson H, Levin A, Nathanson K, Ware E, Weir D, Zhao W, Zhi D, Arnett D, Grant S, Kardina S, Olopade O, Rao D, Rotimi C, Sale M, Williams K, Zemel B, Becker D, Borecki I, Evans M, Harris T, Hirschhorn J, Li Y, Patel S, Psaty B, Rotter J, Wilson J, Bowden D, Cupples L, Haiman C, Loos R, North K. Discovery and Fine-Mapping of Adiposity Loci Using High Density Imputation of Genome-Wide Association Studies in Individuals of African Ancestry: African Ancestry Anthropometry Genetics Consortium. *PLoS Genetics*. 13(4):e1006719 (2017). [PM ID: 28430825](#)
235. Feng Y, Rhie SK, Huo D, Ruiz-Narvaez EA, Haddad S, Ambrosone CB, John EM, Bernstein L, Zheng W, Hu JJ, Ziegler RG, Nyante S, Bandera EV, Ingles SA, **Press MF**, Deming SL, Rodriguez-Gil JL, Zheng Y, Yao S, Han Y-J, Ogundiran TO, Rebbeck TR, Adebamowo C, Ojengbede O, Falusi AG, Simon MS, Hennis A, Nemesure B, Wu S-Y, Leske MC, Ambs S, Chen LS, QF, Gamazon ER, Cox NJ, Blot W, Cai Q, Signorello L, Nathanson KL, Domchek SM, Lunetta KL, Sucheston-Campbell LE, Bensen JT, Chanock SJ, Le Marchand L, Olshan A, Kolonel LN, Conti DV, Coetzee GA, Stram DO, Olopade OI, Palmer JR, Haiman CA. Characterizing Genetic Susceptibility to Breast Cancer in Women of African Ancestry. *Cancer Epidemiology, Biomarkers & Prevention*. 6(7); 1-11, 2017. PMID: 28377418 DOI: [10.1158/1055-9965.EPI-16-0567](#)
236. Walia S, Ma Y, Lu J, Lang J, **Press MF**. Pathology and Current Management of Borderline Breast Epithelial Lesions. *American Journal of Hematology / Oncology* 13(8): 24-31 2017.
237. **Press, MF**, Ma, Y, Groshen S, Sauter G, Slamon DJ. Controversies in HER2 Oncogene Testing: What Constitutes a True Positive Result in Breast Cancer Patients? *American Journal of Hematology / Oncology* 13{9}: 18-28, 2017.
238. Johnston SRD, Hegg R, Im SA, Park IH, Burdaeva O, Kurteva G, **Press MF**, Tjulandin S, Iwata H, Simon SD, Kenny S, Sarp S, Izquierdo MA, Williams L, Gradishar WJ. Phase

- III, randomized study of dual Human epidermal growth factor 2 (HER2) blockade with lapatinib plus trastuzumab in combination with an aromatase inhibitor in postmenopausal women with HER2-positive, hormone receptor-positive metastatic breast cancer: ALTERNATIVE. *Journal of Clinical Oncology* 10; 36(8): 741-748, 2018, doi: 10.1200/JCO.2017.74.7824. PMID: 29244528
239. Ma H, Ursin G, Xu X, Lee E, Togawa K, Malone KE, Marchbanks PA, McDonald JA, Simon MS, Folger SG, Lu Y, Sullivan-Halley J, Deapen DM **Press MF**, Bernstein L. Body mass index at age 18 years and recent body mass index in relation to risk of breast cancer overall and ER/PR/HER2-defined subtypes in white women and African-American women: a pooled analysis. *Breast Cancer Research* 20: 5 (2018), PM ID: 29357906
240. Lang JE, Ring A, Porras T, Kaur P, Forte VA, Mineyev N, Tripathy D, **Press MF**, Campo D. RNA Seq of Circulating Tumor Cells in Stage II-III Breast Cancer. *Annals of Surgical Oncology* 25: 2261-2270, 2018, PM ID: 29868978.
241. Garon EB, Siegfried JM, Stabile LP, Young PA, Marquez-Garban DC, Park DJ, Parikh RJ, Patel R, Hu EH, Reckamp KL, Adams B, Martinez D, Elashoff RM, Grogan T, Wang H-J, Kabbinavar F, Dacic S, Brennan M, Valdes Y, Davenport S, Dubinett SM, **Press MF**, Slamon DJ, Pietras RJ. Randomized Phase II Study of Fulvestrant and Erlotinib Compared with Erlotinib Alone in Patients with Advanced or Metastatic Non-Small Cell Lung Cancer. *Lung Cancer* 123: 91-98, 2018. <https://doi.org/10.1016/j.lungcan.2018.06.013> PM ID: 30089602
242. Wolff AC, Hammond MEH, Allison KH, Harvey BE, Mangu PB, Bartlett JMS, Bilous M, Ellis IO, Fitzgibbons P, Hanna W, Jenkins RB, **Press MF**, Spears PA, Vance GH, Viale G, McShane LM, Dowsett M. Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline Focused Update. *Journal of Clinical Oncology* 36 (20): 2105-2122, 2018. DOI: <https://doi.org/10.1200/JCO.2018.77.8738>. PM ID: 29846122
243. Wolff AC, Hammond MEH, Allison KH, Harvey BE, Mangu PB, Bartlett JMS, Bilous M, Ellis IO, Fitzgibbons P, Hanna W, Jenkins RB, **Press MF**, Spears PA, Vance GH, Viale G, McShane LM, Dowsett M. Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline Focused Update. *Archives of Pathology and Laboratory Medicine* 142 (11): 1364-1382, 2018, PM ID: 29846104. <https://doi.org/10.5858/arpa.2018-0902-SA>
244. **Press MF** and Slamon DJ. “Reply to Dr. Steven Sorscher, regarding ‘Controversies in HER2 Oncogene Testing: What Constitutes a True Positive Result in Breast Cancer Patients?’” *American Journal of Hematology / Oncology*, <https://www.gotoper.com/publications/ajho/2017/2017october/controversies-in-her2-oncogene-testing-what-constitutes-a-true-positive-result-in-patients-with-breast-cancer>, 2018.
245. **Press MF**, Kim G, Jamali MMK, Ma Y, Slamon DJ. HER2 Testing in the Era of Changing Guidelines, Chapter 2 in *HER2-Positive Breast Cancer*, Edited by Sara Hurvitz and Kelly McCann, pp. 13-39, 2018\*.

246. Wu NC, Wong W, Ho KE, Chu VC, Rizo A, Davenport S, Kelly D, Makar R, Jassem J, Duchnowska R, Biernat W, Radecka B, Fujita T, Klein JL, Stonecypher M, Ohta S, Juhl H, Weidler JM, Bates M, **Press MF**. Comparison of central laboratory assessments of ER, PR, HER2, and Ki67 by IHC/FISH and the corresponding mRNAs (*ESR1*, *PGR*, *ERBB2*, and *MKi67*) by RT-qPCR on an automated, broadly deployed diagnostic platform. *Breast Cancer Research and Treatment* 172 (2), 327-338, 2018 Aug 17. doi: 10.1007/s10549-018-4889-5. PM ID: 30120700
247. Papp E, Hallberg D, Konecny GE, Bruhm DC, Adleff V, Noë M, Kagiampakis I, Conklin D, Kinose Y, White JR, **Press MF**, Drapkin R, Easwaran H, Baylin S, Slamon D, Velculescu VE, Scharpf RB. Integrated Genomic, Epigenetic, and Expression Analyses of Ovarian Cancer Cell Lines. *Cell Reports* 25, 2617–2633, 2018. PM ID: 30485824
248. Ring A, Ngyuen C, Smbatyan G, Tripathy D, Yu M, **Press M**, Kahn M, Lang J. CBP/ $\beta$ -catenin/FOXO1 is a novel therapeutic target in triple negative breast cancer. *Cancers* 2018, 10, 525; doi:10.3390/cancers10120525
249. Caswell-Jin JL, McNamara K, Reiter JG, Sun R, Hu Z, Ma Z, Ding J, Suarez CJ, Tilk S, Raghavendra A, Forte V, Chin S-F, Bardwell H, Provenzano E, Caldas C, Caldas C, Lang J, West R, Tripathy D, **Press MF**, Curtis C. Clonal replacement and heterogeneity in breast tumors treated with neoadjuvant HER2-targeted therapy. *Nature Communications* 2019 Feb 8;10(1):657. doi: 10.1038/s41467-019-08593-4. PM ID: 30737380
250. **Press MF**, Seoane JA, Curtis C, Quinaux E, Guzman R, Sauter G, Eiermann W, Mackey JR, Robert N, Pienkowski T, Crown J, Martin M, Valero V, Bee V, Ma Y, Villalobos I, Slamon DJ. Assessment of ERBB2/HER2 Status in HER2-Equivocal Breast Cancers by FISH and 2013/2014 ASCO-CAP Guidelines. *JAMA Oncology* 5(3): 366 - 375, 2019. doi:10.1001/jamaoncol.2018.6012. PM ID: 30520947
251. **Press MF**, Xie B, Davenport S, Zhou Y, Guzman R, Nolan GP, O'Brian N, Palazzolo M, Mak T, Slamon DJ. Role for polo-like kinase 4 in cytokinesis. *Proceedings of the National Academy of Sciences of the USA* 116 (23): 11309-11318, 2019.
252. Hurvitz SA, Martin M, **Press MF**, Chan D, Fernandez-Abad M, Petru E, Rostorfer R, Guarneri V, Huang C-S, Barriga S, Wijayawardana S, Brahmachary M, Ebert PJ, Hossain A, Liu J, Abel A, Aggarwal A, Jansen VM, Slamon DJ. Potent cell cycle inhibition and upregulation of immune response with abemaciclib and anastrozole in neoMONARCH, Phase 2 neoadjuvant study in HR+ breast cancer. *Clinical Cancer Research*, in review, 2019.
253. Du Z, Weinhold N, Song C, Rand K, Van Den Berg D, Hwang A, Sheng X, Hom V, Ailawadhi S, Nooka AK, Singhal S, Pawlish K, Peters ES, Bock C, Mohrbacher A, Stram A, Berndt SI, Blot WJ, Casey G, Stevens VL, Kittles R, Phyllis G, Diver WR, Hennis A, Nemesure B, Klein EA, Rybicki BA, Stanford JL, Witte J, Signorello L, John EM, Bernstein L, Stroup A, Olshan A, Zheng W, Hu JJ, Ziegler R, Nyante SJ, Bandera E, Ingles SA, **Press MF**, Carpten JD, Chanock S, Mehta J, Colditz GA, Wolf J, Martin TG, Tomasson M, Fiala MA, Terebelo H, Janakiraman N, Kolonel L, Anderson KC,

- LeMarchand L, Auclair D, Ziv E, Chiu Brian CH, Stram D, Vij R, Bernal-Mizrachi L, Morgan GJ, Zonder JA, Huff CA, Lonial S, Orlowski RZ, Conti DV, Haiman CA, Cozen W. A meta-analysis of genome-wide association studies of multiple myeloma among African Americans. *Blood Advances* (in review), 2019.
254. Mahtani R, Abraham J, Badve S, Caldera H, Coleman R, Mamounas ET, Holmes FA, Kalinsky K; Kittaneh M, Lower E, Pegram M, **Press MF**, Rugo H, Schwartzberg L, Vogel CL. A Roundtable Discussion by the Breast Cancer Therapy Expert Group (BCTEG): Clinical Developments and Practice Guidance on Human Epidermal Growth Factor Receptor 2 (HER2) Positive Breast Cancer. *Clinical Breast Cancer* (in press), 2019.